RNA EDITING ENZYME AND METHODS OF USE THEREOF

Abstract: The present invention provides novel human polynucleotide sequences and the recombinant human DRADA proteins encoded thereby and methods of use thereof.

Description: RNA EDITING ENZYME AND METHODS OF USE THEREOF This invention was funded by Grant No. GM 40536, CA 09171, and CA 10815 from the Department of Health and Human Services. The U.S. Government has certain rights in this invention. Field of the Invention This invention relates generally to the production of proteins via genetic engineering techniques, and more specifically relates to the cloning and use of a novel RNA editing enzyme. Background of the Invention Double-stranded adenosine deaminase (DRADA) is an adenosine deaminase specific for double-stranded RNA (dsRNA) [Bass and eintraub, Cell. 55:1089-1098 (1988); Wagner et al, Proc. Natl. Acad. Sci. USA, 86:2647-2651 (1989) ] . DRADA deaminates multiple adenosine (A) residues to inosines (I) by a hydrolytic dea ination reaction [A. G. Poison et al, Biochem.. 3_0:11507 (1991)] in both inter- and intra-molecular dsRNAs [Nishikura et al, EMBO J.. .10:3523 (1991)], creating I-U mismatched base pairs in dsRNAs. The accumulation of extensive mismatched I-U base pairs in the dsRNA causes unwinding of the RNA double helix. DRADA is the first and so far, the only, RNA-unwinding activity that results in an accompanying base modification on the substrate RNA. This dsRNA unwinding/modifying activity further differs from other dsRNA unwinding activities or RNA helicases in that it seems to bind specifically to dsRNA. Several examples of in vivo interaction of this enzymatic activity with cellular as well as viral gene transcripts have been reported [Kim and Nishikura, Semin. Cell Biol. , 4_:285-293 (1993)]. For instance, maternal fibroblast growth factor gene and also its antisense transcripts seem to be extensively modified by DRADA in Xenopus oocytes undergoing meiosis [Kimelman and Kirschner, Cell, 59_:687 (1989)]. The enzyme is responsible for genesis of defective measles virus with biased hyper utation, which results in lethal human CNS diseases, measles inclusion body encephalitis [Cattaneo et al., Virol.. 55:255 (1988); Bass et al., Cell. 56:331 (1989)]. Furthermore, an adenosine located in a short stem structure of HIV T-AR was reported to be modified to inosine by DRADA in a tat dependent manner [Sharmeen et al., Proc. Natl. Acad. Sci.. USA. .8_8:8096 (1991)]. Because the enzyme introduces changes in the sequence of its substrate RNA, DRADA is anticipated to be involved in the RNA editing process [see, Kim and Nishikura, in RNA Editing, R. Benne, Ed. (Simon and Schuster International, Chichester, England (1993) , pp. 179-192]. Indeed, DRADA now seems to be responsible for at least the RNA editing of glutamate-gated ion channel subunits (glutamate receptor, GluR) which are responsible for the fast excitation of neurons in mammalian brain [M. Higuchi et al, Cell. 75:1361-1370 (1993)]. DRADA is thus implicated in conditions or disorders characterized by the malfunction or deficient functioning of neuronal transmission in mammalian brain, e.g., in disorders such as stroke, Huntingdon's disease, Alzheimers disease and other such neurological conditions, and may also be associated with aging. There is a need in the art for the isolation and recombinant production of the protein which produces the enzymatic activity described for DRADA, to enable its use in genetic engineering, recombinant production of useful proteins and drug development and screening. Summary of the Invention In one aspect, the invention provides novel, isolated polynucleotide sequences encoding human DRADA proteins. The polynucleotide sequences encoding these proteins are illustrated in Figs. 1A - 1J [SEQ ID NO:l].* Fragments of these sequences are also embodied by this invention. These polynucleotide sequences or fragments thereof may also be optionally associated with conventionally used labels for diagnostic or research use. In another aspect, the present invention provides human DRADA proteins characterized by having RNA editing activity. These proteins are isolated from other cellular materials with which they are naturally associated, and have biological activities associated with a DRADA-like RNA editing function. The DRADA proteins, schematically illustrated in Figs. 2A through 2C, are designated herein as a 140kD protein [amino acid 1-1226 of SEQ ID NO: 2], an approximately 93kD protein [aa 404-1226 of SEQ ID NO: 2], and an approximately 88 kD protein [aa 440-1226 of SEQ ID NO: 2]. An approximately 83 kD protein has also been identified on polyacrylamide gel and biochemically purified. Advantageously, one or more of these proteins is capable of being produced recombinantly. In still other aspects, the invention provides an expression vector which contains at least a polynucleotide sequence described above, a host cell transformed with such an expression vector and methods of using these vectors and host cells in the recombinant production of DRADA proteins. In yet a further aspect, the invention provides a polyclonal or monoclonal antibody generated by use of one of these human DRADA proteins or fragments thereof as an immunogen. In another aspect, the invention provides a diagnostic reagent, such as a DNA probe, i.e., an oligonucleotide fragment derived from the polynucleotide sequence encoding one of the proteins of the invention or from the complementary strand. The reagents may be optionally associated with a detectable label. In yet another aspect, the present invention provides a variety of methods for using an above described poly- or oligo-nucleotide sequence, a protein or an antibody, as an agent in a therapeutic composition for treating disorders characterized by deficient or abnormal DRADA. In yet a further aspect, the invention provides methods for use of these novel above-identified proteins, sequences and antibodies in the development and screening of compounds useful as therapeutics for the treatment of neurological disorders and diseases which can affect the central nervous system, such as Alzheimer's disease, HIV or subacute sclerosing panencephalitis (SSPE) . In a further aspect, the present invention provides for compounds or drugs produced by use of the above methods. Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments of the present invention. Brief Description of the Drawings Figs. 1A-1J illustrate the continuous nucleotide and amino acid sequences [SEQ ID NO: 1 and 2] of human DRADA proteins. A putative bipartite nuclear localization signal is boxed. The N-terminal sequences of the 93 kD and 88kD proteins are indicated by the arrows. The three repeats of a dsRNA binding motif (DRBM) are underlined. Fig. 2A illustrates a bar graph which represents the open reading frame (ORF) for a 140 kD form of human DRADA, with the putative nuclear localization signal indicated by a black box (NUC) , and the dsRNA binding motifs (DRBM) indicated by hatching. Fig. 2B illustrates a bar graph which represents the ORF for the 93 kD truncated form of human DRADA, with DRBM indicated by hatching. Fig. 2C illustrates a bar graph which represents the ORF for the 88 kD truncated form of human DRADA, with the DRBM indicated by hatching. Fig. 3 illustrates the restriction map of the ORF of the human DRADA protein with indicated endonuclease enzyme restriction sites and the start (ATG) and stop (TAG) translation codons, and the overlapping human cDNA clones, HUC 1 through 4. Fig. 4A illustrates a bar graph of plasmid pVLDRADA140, with the putative nuclear localization signal indicated by a black box (NUC) , and the DRBM indicated by hatching. Fig. 4B illustrates a bar graph of plasmid pVLDRADAΔ with the putative nuclear localization signal indicated by a black box (NUC) , and the dsRNA binding motifs (DRBM) indicated by hatching. Fig. 5 illustrates a comparison between the three DRBM of human DRADA, indicated as DRADA-1 [SEQ ID NO: 3], DRADA-2 [SEQ ID NO: 4] and DRADA-3 [SEQ ID NO: 5] and by underlining in Figs. 1A - 1J, and the DRBM of other dsRNA binding proteins obtained from Genbank and EMBL databases, including P68kinase-1 [SEQ ID NO: 6], P68kinase-2 [SEQ ID NO: 7], TIKkinase-1 [SEQ ID NO: 8], TIKkinase-2 [SEQ ID NO: 9], HuTRBP-1 [SEQ ID NO: 10], HuTRBP-2 [SEQ ID NO: 11], HuTRBP-3 [SEQ ID NO: 12], X1TRBP-1 [SEQ ID NO: 13], X1TRBP-2 [SEQ ID NO: 14], X1TRBP-3 [SEQ ID NO: 15], Staufen-1 [SEQ ID NO: 16], Staufen-2 [SEQ ID NO: 17], Staufen-3 [SEQ ID NO: 18], Staufen-4 [SEQ ID NO: 19], Staufen-5 [SEQ ID NO: 20], Huson-a [SEQ ID NO: 21], E3L [SEQ ID NO: 22], Ns34 [SEQ ID NO: 23], Pad [SEQ ID NO: 24], RNase III [SEQ ID NO: 25] and a Consensus sequence based on all of these sequences [SEQ ID NO: 26] . The amino acids in bold print indicate the most frequently occurring amino acids in a common position among the sequences listed in this figure. The location of the α-helix is also indicated. Detailed Description of the Invention The present invention provides isolated and characterized human DNA sequences encoding a double stranded RNA adenosine deaminase enzyme (DRADA) , and fragments thereof. DRADA and its protein fragments are responsible for mRNA editing of generations of glutamate- gated ion channel subunits. The provision of the polynucleotide sequences of this invention permits DRADA proteins to be produced by expression of the sequence in recombinant host cells. Because they are produced by recombinant techniques, both the nucleotide sequences and resulting expressed proteins are free from contamination with other sequences, cellular materials or protein materials with which the nucleotide and protein sequences occur in nature. I. The DRADA Proteins The DRADA protein is characterized by an approximately 1226 amino acid protein sequence and an apparent molecular weight of approximately 140kD [SEQ ID NO:2] (See, Figs. 1A - 1J) . Included in this invention are fragments of the DRADA protein. Preferably, the 140 kD DRADA and these fragments are characterized by sharing the dsRNA deaminase activity. The DRADA fragments of this invention are biologically active and have similar biological activity to full-length human DRADA. Particularly desirable are the following fragments which have been found to be N-terminal truncated versions of DRADA: a DRADA protein spanning amino acids 404 to 1226 of SEQ ID NO: 2 and having an apparent molecular weight of 93 kD; and a DRADA protein spanning amino acids 440 to 1226 of SEQ ID NO: 2 and having an apparent molecular weight of 88 kD. A DRADA protein having an apparent molecular weight of 83 kD on the polyacrylamide gel and which was biochemically purified has also been identified. Also included in the invention are analogs, or modified versions, of the DRADA proteins provided herein. Typically, such analogs differ by only 1, 2, 3 or 4 codon changes and are characterized by DRADA-like biological activity. Examples include polypeptides with minor amino acid variations from the illustrated amino acid sequences of DRADA (Figs. 1A - 1J; SEQ ID NO:2); in particular, conservative amino acid replacements. Conservative replacements are those that take place within a family of amino acids that are related in their side chains and chemical properties. Additionally, the DRADA proteins [SEQ ID NO:2] of the invention may be modified, for example, to improve production thereof, to enhance protein stability or other characteristics, e.g. binding activity or bioavailability, to enhance its use for screening competitive compounds or to confer some other desired property upon the protein. For example, the catalytic domain of DRADA located in the carboxyl terminus at about amino acid 797 to 1226 of SEQ ID NO: 2 may be separately excised to obtain a DRADA protein more useful for screening compounds. Alternatively, a DRADA protein of the invention may be truncated or modified to remove the putative nuclear localization signal indicated in Figs. 1A - 1J at amino acids 169-170 and 181-185 of SEQ ID NO:2. Similarly, if desired, the dsRNA binding sites indicated in Fig. 3 by underlining at amino acids 502-573 of SEQ ID NO:2 (DRBM1) , at amino acids 703-684 of SEQ ID NO:2 (DRBM2), and at amino acids 725-796 of SEQ ID NO:2 (DRBM3) may be modified by deletion or modification of one or more amino acid residues to provide alternate targets for the screening of compounds capable of binding thereto and inhibiting the function of DRADA. Similarly, the phosphorylation sites on DRADA, which may be identified by their known motifs on a variety of conventional computer programs, may be excised or altered for use in screening for binding or inactivating compounds. Sequence analysis indicates that DRADA is a new member of the double stranded RNA (dsRNA) binding protein family. The adenosine-to-inosine conversion activity of the DRADA protein encoded by the cloned cDNA was confirmed by recombinant expression in insect cells. Use of the cloned DNA as a molecular probe documented sequence conservation across mammals, and detected a single transcript of 7 kb in RNA of all human tissues analyzed. The deduced primary structure of human DRADA revealed a bipartite nuclear localization signal, three repeats of dsRNA binding motifs, and the presence of sequences conserved in the catalytic center of deaminases, including a cytidine deaminase involved in the RNA editing of apolipoprotein B. It is anticipated that DRADA is involved in other gene systems, and that target genes exist, in addition to the glutamate-gated ion-channel subtype GluR-B transcripts, in different tissues. DRADA may be used in an editing capacity for these additional targets. Using the recombinantly expressed DRADA protein of the invention either in Spodoptera frugiperdeia insect cells or 293 mammalian cells, the inventor has directly demonstrated that DRADA is capable of editing the GluR-B RNAs in vitro . The DRADA proteins of this invention are useful in therapeutic compositions, as described in more detail in part VI below. These proteins may also be useful in diagnostic applications, as well as for generation of other therapeutic and diagnostic reagents, such as anti- DRADA antibodies. In common with other proteins generally, these newly-identified DRADA proteins may also serve as molecular weight markers or in other aspects in screening assays or as research tools. More desirably, the DRADA proteins are also useful for the screening and development of chemical therapeutic agents useful for preventing or enhancing the action of DRADA and thereby correcting the ion channel expression. II. DRADA Polynucleotide Sequences The DRADA gene spans 80 Kb pairs and harbors 16 exons. The transcription of the DRADA gene driven by the putative promoter region with a typical TATA box is initiated approximately 180 nucleotides upstream of the translation initiation codon. Three dsRNA binding motifs or domains, each about 70 amino acid residues long, are encoded by two exons with an intervening sequence interrupting each motif at the identical amino acid position; thus, indicating that the dsRNA binding domains may be composed of two separate functional subdomains. Fluorescent in situ hybridization localized the DRADA gene to the long arm of chromosome lq21 region. The approximately 6671 bp polynucleotide sequence of the human DRADA cDNA is provided in Figs. 1A - 1J [SEQ ID NO:l]. These sequences have been deposited in the GenBank data base (Accession No. U10439) . It encodes the approximately 1226 amino acid protein sequence for the full-length DRADA protein, and portions of this polynucleotide sequence encode the N- terminal deletion proteins of DRADA having apparent molecular weights of 93, 88 and 83 kD. The nucleotide sequence of DRADA contains a short 5' untranslated region (154 bp) , and a long 3' untranslated region (3336 bp) , including a polyadenylate tract of 99 bases. It is currently not known whether this DNA contains the 5' end or cap site of DRADA mRNA. As shown in Fig. 2A, DRADA contains a single ORF (thin open box) . In addition to the polynucleotide fragments encoding the truncated DRADA protein sequences mentioned above, other fragments of these sequences may prove useful for a variety of uses. Desirably, these fragments are at least about 15 nucleotides in length and encode a desired amino acid sequence, e.g. an epitope, a therapeutically useful peptide desirably characterized by DRADA-like biological activity, or the like. These nucleotide sequences of the invention may be isolated as by conventional uses of polymerase chain reaction or cloning techniques such as those described in obtaining the bovine and human sequences in Examples 1 and 3, described below. Alternatively, these sequences may be constructed using conventional genetic engineering or chemical synthesis techniques. According to the invention, the nucleic acid sequence [SEQ ID NO: 1] coding for the encoded DRADA proteins [SEQ ID NO: 2] described above and provided in Figs. 1A - 1J, may be modified. Utilizing the sequence data in these figures, it is within the skill of the art to obtain other polynucleotide sequences encoding the proteins of the invention. Such modifications at the nucleic acid level include, for example, modifications to the nucleotide sequences which are silent or which change the amino acids, e.g. to improve expression or secretion. In still another alternative, the polynucleotide sequences may be modified by adding readily assayable tags to facilitate quantitation, where desirable. Nucleotides may be substituted, inserted, or deleted by known techniques, including, for example, in vitro mutagenesis and primer repair. Also included are allelic variations, caused by the natural degeneracy of the genetic code. In addition to isolated nucleic acid sequences [SEQ ID NO: 1] encoding the DRADA protein [SEQ ID NO: 2] described herein, this invention also encompasses other nucleic acid sequences, including those complementary to the illustrated DNA sequences, such as antisense sequences. Useful DNA sequences also include those sequences which hybridize under high or moderately high stringency conditions [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual) . Cold Spring Harbor Laboratory (1982) , pages 387 to 389] to the DNA sequences illustrated in Figs. 1A - 1J. An example of a highly stringent hybridization condition is hybridization at 4XSSC at 65°C, followed by a washing in O.IXSSC at 65°C for an hour. Alternatively, an exemplary highly stringent hybridization condition is in 50% formamide, 4XSSC at 42°C. Other, moderately high stringency conditions may also prove useful, e.g. hybridization in 4XSSC at 55°C, followed by washing in O.IXSSC at 37°C for an hour. Alternatively, an exemplary moderately high stringency hybridization condition is in 50% formamide, 4XSSC at 30°C. The nucleic acid sequences encoding these proteins are themselves useful for a variety of diagnostic and therapeutic uses. Advantageously, the nucleic acid sequences are useful in the development of diagnostic probes and antisense probes for use in the detection and diagnosis of various genetic disorders characterized by deficient or aberrant DRADA enzymes and glutamate-gated ion-channel communication. Oligonucleotide probes may be useful in such standard diagnostic techniques as Southern blotting and polymerase chain reaction. See discussion in parts V and VI below. The nucleic acid sequences of this invention are also useful in the production of human DRADA proteins. Once constructed, or isolated, as described in further detail in Example 1 below, these DNA sequences or suitable fragments are preferably employed to obtain proteins of this invention. III. Recombinant Expression of DRADA To produce recombinant DRADA proteins of this invention, the DNA sequences of the invention are inserted into a suitable expression system. Desirably, a recombinant molecule or vector is constructed in which the polynucleotide sequence encoding DRADA is operably linked to a heterologous expression control sequence permitting expression of the human DRADA protein. Numerous types of appropriate expression vectors and host cell systems are known in the art for mammalian (including human) expression, insect, e.g., baculovirus expression, yeast, fungal, and bacterial expression, by standard molecular biology techniques. The transformation of these vectors into appropriate host cells can result in expression of the selected DRADA proteins. Other appropriate expression vectors, of which numerous types are known in the art, can also be used for this purpose. Suitable host cells or cell lines for transfection by this method include insect cells, such as Spodoptera frugipedera (Sf9) cells. Methods for the construction and transformation of such host cells are well-known. [See, e.g. Miller et al, Genetic Engineering. 8 . :277-298 (Plenum Press 1986) and references cited therein] . Similarly, mammalian cells, such as Human 293 cells, Chinese hamster ovary cells (CHO) , the monkey COS- l cell line or murine 3T3 cells derived from Swiss, Balb- c or NIH mice may be used. Suitable mammalian host cells and methods for transformation, culture, amplification, screening, and product production and purification are known in the art. [See, e.g., Gething and Sambrook, Nature. 293:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol.. 5(7) : 1750-1759 (1985) or Howley et al, U. S. Patent 4,419,446]. Another suitable mammalian cell line is the CV-1 cell line. Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of E. coli (e.g., HB101, MC1061, and strains used in the following examples) are well-known as host cells in the field of biotechnology. Various strains of B . εubtilis , Pseudomonas , other bacilli and the like may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. Other fungal cells may also be employed as expression systems. Thus, the present invention provides a method for producing a recombinant human DRADA protein which involves transforming a host cell with at least one expression vector containing a recombinant polynucleotide encoding a human DRADA protein under the control of a transcriptional regulatory sequence, e.g. by conventional means such as transfection or electoporations. The transformed host cell is then cultured under suitable conditions that allow expression of the human DRADA protein. The expressed protein is then recovered, isolated, and purified from the culture medium (or from the cell, if expressed intracellularly) by appropriate means known to one of skill in the art. For example, the proteins may be isolated following cell lysis in soluble form, or extracted in guanidine chloride. If desired, the DRADA proteins of the invention may be produced as a fusion protein. For example, it may be desirable to produce such DRADA fusion proteins, to enhance expression of the protein in a selected host cell, or to improve purification. Suitable fusion partners for the DRADA proteins of the invention are well known to those of skill in the art and include, among others, β-galactosidase and poly-histidine. IV. Production of Anti-DRADA Antibodies The DRADA proteins of this invention are also useful as antigens for the development of specific antibodies, both polyclonal and monoclonal, to DRADA or various portions of the DRADA proteins, such as the DRBM or catalytic regions. Antibodies may also be developed to modified versions or analogs of DRADA. These antibodies may be produced by conventional methods, including the Kohler and Milstein hybridoma technique, recombinant techniques, such as described by Huse et al, Science. 246:1275-1281 (1988), or any other modifications thereof known to the art. V. Diagnostic Reagents The proteins, antibodies, and polynucleotide sequences (including anti-sense polynucleotide sequences) of this invention may be useful as diagnostic reagents for diagnosing certain neurological or central nervous system disorders, e.g., Alzheimer's disease, Huntingdon's disease, SSPE, measles inclusion body encephalitis, strokes and other conditions, including aging, which are found to be associated with abnormal or deficient expression of DRADA. For example, a protein, antibody, or polynucleotide of the invention may be utilized to diagnose a naturally-occurring mutation in DRADA characteristic of such a condition. These reagents may optionally be labelled using diagnostic labels, such as radioactive labels, colorimetric enzyme label systems and the like conventionally used in diagnostic or therapeutic methods. The reagents may measure abnormal DRADA levels or detect mutant DRADA enzymes in selected mammalian tissue in conventional diagnostic assays, e.g., Southern blotting, Northern and Western blotting, polymerase chain reaction and the like. For example, as diagnostic agents the polynucleotide sequences may be employed to detect or quantitate normal or mutant DRADA mRNA or detect mutations in target gene RNA in a patient sample. The selection of the appropriate assay format and label system is within the skill of the art and may readily be chosen without requiring additional explanation by resort to the wealth of art in the diagnostic area. Thus the present invention provides methods for the use of these protein, antibody or polynucleotide reagents in the diagnosis of disorders characterized by neurological symptoms, such as the malfunction of glutamate-gated ion-channels or detection of genetic diseases. The methods involve contacting a selected mammalian tissue, e.g., skin, cerebrospinal fluids, or other cells with the selected reagent, protein, antibody or DNA sequence, and measuring or detecting the amount of DRADA present in the tissue in a selected assay format based on the binding or hybridization or the reagent to the tissue. VI. Therapeutic Reagents Alternatively, the DRADA proteins or nucleotide sequences may be useful as therapeutic reagents for delivery of biologically active DRADA to mammalian tissue. As one example, the recombinant protein may itself be administered by appropriate routes in a pharmaceutical composition to correct the malfunctioning of or defects in glutamate-gated ion channels, which can result in neurological disorders such as Alzheimer's disease, seizures and strokes. Alternatively, a desired DRADA nucleic acid sequence of the invention may be incorporated into a suitable vector or other delivery system. Suitable delivery systems are well known to those of skill in the art. Vectors containing such sequences may be administered, thus, treating deficiencies of DRADA via in vivo expression of the proteins of the invention. Such delivery systems enable the desired DRADA gene to be incorporated into the target cell and to be translated by the cell. Still another method involves the use of the DRADA polynucleotide sequences for gene therapy. In the method, the DRADA sequences are introduced into a suitable vector for delivery to a cell containing a defect in the DRADA gene. By conventional genetic engineering techniques, the DRADA gene sequence may be introduced to mutate the existing gene by recombination or in addition to the inactive gene to replace it. According to the above methods, a recombinant DRADA protein of the invention can be provided to a cell, particularly a cell in an individual having a condition characterized by a deficiency in DRADA. Such therapeutic uses are anticipated for disorders characterized by neurological symptoms and caused at least in part by the lack of active DRADA or the presence of abnormal or inactive DRADA enzyme in mammalian tissue. For example, it is anticipated that DRADA activity levels may change during the aging process. In such a circumstance, a therapeutic of the invention may be utilized to regulate DRADA activity to more desirable levels. As defined herein, a therapeutic of the invention may include the DRADA antibodies of the invention, which antibodies may be used to block inappropriate DRADA activity, e.g., by blocking binding of DRADA at a substrate-binding site, particularly DRBM1 or DRBM3. VII. Drug Screening and Development The proteins, antibodies and polynucleotide sequences of the present invention may also be used in the screening and development of chemical compounds or proteins which have utility as therapeutic drugs for the treatment of neurological disorders, such as those identified above. As one example, a compound capable of binding to DRADA and either preventing or enhancing its biological activity may be a useful drug component for the treatment or prevention of neurological disorders characterized by defect in the ion channel expression, or diseases such as SSPE or measles inclusion body encephalitis. In the former case, the drug may work by correcting channel expression. In the latter case, the drug may work by preventing the DRADA enzyme from mutating the relatively harmless measles virus into its lethal form. Additionally, based on the similarities of the DRADA DRBM and sequences within the HIV TAR binding protein, HuTRBP, and other dsRNA proteins, a compound identified as binding to, and/or blocking the DRADA DRBM or catalytic domain, may be a useful drug component for the treatment of HIV [Shar een et al, cited above] or other disease agents which invade the mammalian cell via a similar sequence (See Fig. 5) . Presently, conventional assays and techniques exist for the screening and development of drugs capable of competitively binding to selected regions of DRADA, such as the DRBM or catalytic domains. These include the use of phage display system for expressing the DRADA proteins or portions thereof, e.g., DRBMs, and using a culture of transfected E. coli or other microorganism to produce the proteins for binding studies of potential binding compounds. See, for example, the techniques described in G. Cesarini, FEBS Letters. 307(1) :66-70 (July 1992); H. Gram et al, J. Immunol. Meth.. 161:169- 176 (1993); C. Summer et al, Proc. Natl. Acad. Sci.. USA. ^ : 3756-3760 (May 1992), incorporated by reference herein. Other conventional drug screening techniques may be employed using the proteins, antibodies or polynucleotide sequences of this invention. As one example, a method for identifying compounds which specifically bind to DRADA DNA sequences can include simply the steps of contacting a selected DRADA DNA fragment, e.g., a DRBM fragment of SEQ ID NO: 1, with a test compound to permit binding of the test compound to the DNA fragment; and determining the amount of test compound, if any, which is bound to the DNA fragment. Such a method may involve the incubation of the test compound and the DRBM DNA fragment immobilized on a solid support. Another method of identifying compounds which specifically bind to DRADA DNA binding sequences can include the steps of contacting a DRADA DRBM DNA fragment immobilized on a solid support with both a test compound and the protein sequence which is the normal binding partner of the DRADA DRBM to permit binding of the normal binding partner protein to the DRADA DNA fragment; and determining the amount of the normal binding partner protein which is bound to the DNA fragment. The inhibition of binding of the normal protein by the test compound thereby indicates binding of the test compound to the DRADA DRBM DNA sequences. Still other conventional methods of drug screening can involve employing a suitable computer program to determine compounds having similar or complementary chemical structures to that of the DRADA DRBM, and screening those compounds either for competitive binding to DRADA DRBM and/or using the base modification assay described below to detect enhanced or decreased DRADA activity in the presence of the selected compound. Thus, through use of such methods, the present invention is anticipated to provide compounds capable of interacting with DRADA or portions thereof, and either enhancing or decreasing its biological activity, as desired. Such compounds are believed to be encompassed by this invention. It should be understood that one of skill in the art may readily select the type of conventional screening method most desirable, as well as the reagent of this invention, e.g., the DRADA protein, nucleotide sequence, or fragment thereof or an antibody developed by use of such DRADA proteins. The following examples which disclose the cloning and expression of human DRADA are for illustrative purposes only, and should not be construed as limiting this invention in any way. Example 1 - Isolation of Bovine DRADA Protein Using an assay for modified bases designed to detect inosine converted from adenosines described below and according to methods described by Wagner and Nishikura, (1988) and Wagner et al., (1989), both cited above, a DRADA homolog was isolated from bovine liver nuclear extracts as follows: A. Preparation of Nuclear Extract Nuclear extract was prepared from bovine liver by the method described by Dignam et al, Nucleic Acids Res.. 11 '1475-1489 (1983) with the following modifications. All procedures were carried out at 4°C. Fresh bovine liver (1 Kg) , obtained from a local slaughterhouse, was minced using a blender, and further homogenized by a motor-driven Potter-homogenizer in 3 times the packed cell volume of a buffer containing 10 mM Hepes (pH 7.6), 25 mM KC1, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M sucrose, and 10% glycerol. After centrifugation at 30,000 rpm in a Type 45 Ti Beckman rotor for 30 minutes, the nuclear pellet was suspended in a hypertonic buffer containing 0.02 M Hepes (pH 7.9), 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 0.5 mM dithiothreitol (DTT) , and 0.5 mM PMSF. After two strokes in a glass dounce- homogenizer, the protein extract was cleared of debris by centrifugation at 30,000 rpm for 30 minutes. The activity was precipitated by adding solid (NH 4 ) 2 S0 4 to 55% saturation (0.33 g/ml) and stirring for 1 hour at 4°C. After centrifugation at 35,000 rpm for 1 hour, the pellet was resuspended in a small volume (-1/10 volumes of initial cell pellets) of buffer A [0.02 M Hepes (pH 7.5), 5 mM EDTA, 1 mM DTT, 17% glycerol, and 0.25 mM PMSF] containing 0.15 M KC1, and dialyzed against three changes of 2 L of the same buffer to remove (NH 4 ) 2 S0 4 . The final nuclear extract was cleared by centrifugation at 30,000 rpm for 30 minutes and frozen in liquid nitrogen in aliquots. Typically, 1 Kg of liver yielded approximately 5 g of nuclear extract proteins. B. ssDNA Agarose Column and First Cycle of Poly(I) ♦Poly(C) Agarose Column All column chromatography procedures were carried out at 4°C. Approximately 5 g of crude nuclear extract (after adjusting salt concentration to 0.35 M KC1) was passed through 85 ml (2.6 x 16 cm) of ssDNA agarose column equilibrated with buffer A containing 0.35 M KC1 at a flow rate of 20 ml/hour. The enzyme did not bind to the ssDNA and was found in the flow-through fraction. The ssDNA column served to remove certain ssDNA binding proteins that would otherwise also bind to the dsRNA column. The flow-through containing the activity, which was immediately loaded onto 50 ml (2.6 x 10 cm) of poly(I) -poly(C) dsRNA agarose column that has been equilibrated with buffer A containing 0.35 M KC1. The poly(I) -poly(C) column was washed sequentially with 100 ml of buffer A containing 0.5 M KC1 and then 100 ml of buffer A with 1.0 M KC1 at a flow rate of 20 ml/hour. The enzyme bound to the poly(I) * *poly(C) duplexes very tightly under the conditions used, allowing other dsRNA binding proteins to be washed from the column with high salt buffer (up to 1.0 M KCl) . The enzyme was eluted by raising the salt concentration of the buffer. The activity was eluted with 100 ml of buffer A containing 3.0 M KCl and 0.2% Nonidet-P40 (NP40) at a flow rate of 10 ml/hour. NP40 (0.1-0.2%) was added to buffers in all of the subsequent steps of purification in order to prevent the loss of the dilute enzyme. Fractions of 10 ml each were collected and assayed for base modification activity of Example 2 to identify the active fractions. The 3.0 M KCl fraction contained two major polypeptides with apparent molecular weights of 93 and 88 kD as judged by SDS-PAGE stained with silver. C. Second Cycle of Poly(I) •Polv(C) Agarose Column To further purify the enzyme from minor contaminants, the 3.0 M KCl fraction was rechromatographed through a second purification cycle on the poly(I) •poly(C) column. Active fractions from the first cycle of poly(I) -poly(C) agarose column were pooled, diluted to 0.35 M KCl with buffer A containing 0.2% NP40, and passed through a second cycle of 50 ml poly(I) -poly(C) agarose column. The column was washed and eluted as for the first poly(I) •poly(C) column, except that all buffers contained 0.2% NP40. Active fractions purified by two cycles of dsRNA affinity column chromatography were then concentrated by DEAE CL-6B ion exchange column chromatography. D. DEAE CL-6B Ion Exchange Column The active fractions from the second poly(I) -poly(C) agarose column were pooled and dialyzed against two changes of 2 L of buffer B [0.02 M Hepes (pH 7.9), 5 mM EDTA, 1.0 mM DTT, 17% glycerol, and 0.25 mM PMSF] containing 0.05 M KCl and 0.2% NP40 for 8 hours. The dialyzed fraction was passed through 1.0 ml (1.0 x 1.3 cm) DEAE CL-6B (Pharmacia), equilibrated with buffer B containing 0.05 M KCl and 0.2% NP40 at a flow rate of 4 ml/hour. After washing the column with 4 ml of buffer B containing 0.05 M KCl and 0.2% NP40, the activity was eluted with 10 ml of buffer A containing 3.0 M KCl and 0.2% NP40. Active fractions were identified by base modification assay of Example 2. The final purified fraction containing the 93 kD and 88 kD polypeptides was estimated to be enriched about 22,000-fold over the initial liver homogenate in DRADA activity with a yield of 0.16% and was fractionated by SDS-PAGE (7% gel) , and visualized by silver staining. Molecular weight standards used were 2-macroglobulin (108 kD) , β-galactosidase (116kD) , phosphorylase B (94 kD) , bovine serum albumin (67kD) , pyruvate kinase (58kD) , fumarase (48.5 kD) , lactic dehydrogenase (36.5 kD) , and carbonic anhydrase (30 kD) . The gel revealed three major peptides with apparent molecular weights of 93, 88, and 83 kD. These three proteins behaved identically on a two-dimensional isoelectrofocusing gel and also produced nearly identical peptide cleavage patterns after digestion with trypsin. Example 2 - DRADA Assay and Base Modification Assay A. DRADA Assay DRADA was assayed in vitro [Bass et al, Cell. 4£:607-613 (1987); Wagner et al, Mol. Cell. Biol.. 8 . :770-777 (1988)]. Unless specified otherwise, the reaction was carried out in 100 μl reaction, which contained 10 fmol of α-[ 32 P]ATP-labeled c-myc dsRNA or human α-globin dsRNA [Wagner et al, cited above; Nishikura et al, EMBO J.. 10:3523-3532 (1991)], 0.05 M Tris (pH 7.0), 0.2 M NaCl, 5 mM EDTA, 1 mM DTT, and 20% glycerol, and various amounts of bovine liver nuclear extract proteins or 20 ng of purified DRADA proteins. After incubation for 1 hour at 37°C, the reaction products were deproteinized and then precipitated with ethanol, as described previously [Wagner et al, cited above; Wagner et al, Proc. Natl. Acad. Sci. USA, 86:2647- 2651 (1989) ] . The extracted RNAs were analyzed with the below-described base modification assay. B. Base Modification Assay The DRADA activity was followed by determining the amount of adenosine converted to inosine by a fixed volume of each fraction in an in vitro base modification assay as follows. After the DRADA reaction, the RNA samples, together with 10 μg of Escherichia coli tRNA, were digested with nuclease P-L into 5'- mononucleotides. The digests were analyzed by one- dimensional thin layer chromatography (TLC) . The solvent system used was 0.1 M sodium phosphate (pH 6.8) /ammonium sulfate/1-propanol, 100:60:2 (v/w/v) as described in SilverKlang et al, Methods Enzymol.. 59:58-109 (1979). The radioactivity of the adenosine and inosine spots on TLC plates was quantified by the Phosphor Imaging System (Molecular Dynamics, Sunnyvale, California) . Example 3 - Obtaining Bovine Clones Bovine cDNA clones coding for the NH 2 -terminus of 93 and 88 kD proteins were obtained by the method of multiple oligo-primed PCR amplification of cDNA (Lee and Caskey, in PCR Protocols : A Guide to Methods and Application , M. A. Innis et al, Eds., (Academic Press, Inc., San Diego, CA 1990), pp. 47-53. A. Reverse-Transcriptase Polymerase Chain Reaction In brief, degenerate sets of oligonucleotides that represented the codons for NH 2 - terminal peptide sequences were synthesized. For the 93 kD protein, the sense primer was SEQ ID NO: 27: 5 'CCGGAATTCNGGNAAA/GGTNGA3 ' , and the antisense primer was SEQ ID NO: 29: 5'CGGGATCCNGCT/CTCCTT/CTGGT/CTTNA. which correspond to amino acid residues SEQ ID NO: 28: PGKVE and SEQ ID NO: 30: AEQKL, respectively. For the 88 kD protein, the sense primer was SEQ ID NO: 31: 5'CGGAATTCAAA/GACNGGNTAC/TGTNGA3 ' , and the antisense primer was SEQ ID NO: 33: 5 'CGGGATCCG/ATCG/ATCNGGG/T/AATG/ATCG/ ATC3", which correspond to residues SEQ ID NO: 32: KTGYVD and SEQ ID NO: 34: DDPIDD, respectively. Restriction sites for EcoRI for the sense primer and BamHI for the antisense primer were included at the 5' end and are underlined in the sequences above. In addition, internal probes representing the residues flanked by the sense and antisense primers were synthesized. The sequence of the internal probe for the 93 kD protein was SEQ ID NO: 35: 5-C/TTTG/CACG/CACG/T/AGGCTCCTG3' , and for the 88 kD protein was SEQ ID NO: 36: 5 'CGGGATCCAT/CTGNCCA/GTTC/TTCT/GTT3 ' . All possible degenerate codons were included for the sense and antisense primers. For the internal probes, only the codons preferred in bovine genomes were included. The first-strand cDNA synthesis was carried out using total RNA prepared from the cultured bovine endothelial cell line, BFA-1C BPT [J. Grinspan et al, J. Cell Phvsiol.. 114:328-338 (1983)] and a GeneA p® RNA PCR kit (Perkin Elmer Cetus) in a 20 μl reaction containing lOmM Tris-Cl (pH 8.3), 5 mM MgCl 2 , 50mM KCl, 1 mM each dA/G/C/TTP, 1 unit RNase inhibitor, 400 ng antisense primer, 2.5 unit/μl reverse transcriptase and 1 μg total RNA at 42°C for 1 hour. The reaction was terminated by incubating the tubes at 99°C for 5 minutes. B. Screening of the Recombinant Library The PCR was done in a 100 μl reaction containing 10 mM Tris-Cl (pH 8.3), 50 mM KCl, 2 mM MgCl 2 , 4 μM each of sense and antisense primers, 2.5 unit .AmpliTaq DNA polymerase. Amplification was performed in a thermal cycler with 35 cycles of 95°C for 30s, 48°C for 1 min, 70°C for 1 minute. A portion of the amplified product was analyzed by Southern hybridization at 42°C in 6X SSC, 0.1% sodium pyrophosphate, 0.1% SDS, 0.1% Denhardt's, 50mM Tris-Cl (pH 7.5), and 100 μg single- stranded DNA, using the internal probe labeled with [gamma- 32 P] ATP [see Example 6]. The 75 bp cDNA that hybridized to the internal probe was purified from an agarose gel, digested with EcoRI and BamHI, and ligated with pBluescript KS+ plasmid. Selected subclones were sequenced using the sense and antisense primers. Sets of nested deletion mutants of the cDNA clones were generated using exonuclease III and mungbean nuclease [Ansubel et al, Current Protocols in Molecular Biology. Current Protocols, New York, NY (1993)]. The deleted clones were sequenced by either Sequenase (U. S. Biochemicals) or Taq Dye Deoxy Terminator Cycle Sequencing Kit, and analyzed by the 373A DNA Sequencing system (Applied Biosystems) . The overlapping sequences of subclones were aligned and combined by the Fragment Assembly program of the University of Wisconsin Genetics Computer Group (GCG) sequence analysis software package, Version 7.0 [Devereux et al, cited above]. Two cDNA clones were chosen for subsequent experiments, and named BUC1 and BUC2, which coded for the NH 2 -terminus of the bovine DRADA 93 kD and 88 kD proteins, respectively. Amino acid sequence of the NH 2 -terminus of both the bovine 93 and 88 kD proteins, which are not blocked by acylation, were determined by microsequencing. Example 4 - Obtaining the Human DRADA cDNA A recombinant cDNA library in the Lambda Zap®II vector was made from human natural killer (NK) cells isolated from human blood, which cells are known to contain a high level of DRADA activity. The library was screened by the method of Maniatis et al., cited above, using the BUC2 clone as a specific probe. The purified positive lambda phage was converted to a pBluescript plasmid by the in vivo excision method described in Stratagene's manual. The resultant cDNA plasmid, HUC1, contained approximately 4- kb of insert DNA, which hybridized to both BUCl and BUC2 by Southern blot analysis. The insert of HUC1 was then used to rescreen the original cDNA library, from which additional cDNA clones, HUC 2, 3 and 4, were obtained. The four cDNA clones were sequenced and found to be overlapping, as illustrated in Figs. 1A and IB. The structure of cDNA and human DRADA protein was deduced from these clones. Following restriction site mapping to align the multiple overlapping cDNA clones, the nucleotide sequence of 6671 base pairs (bp) [SEQ ID N0:1] was determined for human DRADA. Human DRADA polynucleotide sequence of 6671 base pairs contains a short 5' untranslated region (154 bp) , and a long 3' untranslated region (2839 bp) , including a polyadenylate tract of 99 bases (GenBank Accession No. U10439) . This cDNA may contain the 5' end and/or cap site of DRADA mRNA. As shown in Fig. 2A, DRADA contained a single ORF (thin open box) which encodes a 1226-amino acid protein [SEQ ID NO: 2] with a calculated molecular mass of 136 kD. The proposed initiation codon is in agreement with the mammalian translation initiation consensus sequence [M. Kozak, J. Cell Biol.. 108:229-241 (1989)] and is preceded by an in- frame stop codon. The deduced amino acid sequence of this ORF is shown in Figs. 1A - 1J [SEQ ID NO:2]. The ORF contained the NH 2 -terminal sequences of both p93 and p88 kD protein, which appear to be both truncated forms, lacking, respectively, 403 and 439 amino acid residues of the NH 2 -terminus of the full length 136- kDa DRADA protein (see Figs. 2A through 2C by thick open boxes and in Figs. 1A - 1J by arrows) . A putative bipartite nuclear localization signal is indicated in Fig. 2A by NUC, and a filled box and by boxing in Figs. 1A - 1J. Three dsRNA binding motif (DRBM) repeats are indicated in Figs. 1 and 2, as underlining or hatched boxes, respectively. Example 5 - Expression of Human DRADA Confirmation that the cDNA clone isolated does indeed code for DRADA was obtained by expressing this protein in Spodoptera frugipedera (Sf9) cells as a recombinant baculovirus protein. Two recombinant constructs that coded for a full-length DRADA protein (pVLDRADA140) or a mutant lacking the C-terminal 346 amino acids (pVLDRADAΔ) were made. For pVLDRADA140, Xbal to Kpnl (the 5' end; 3.7 kb) of HUCl and Kpnl to Xbal (the 3' end; 1 kb) fragments of HUC2 were ligated into the commercially available baculovirus expression vector, pVL1393 (Invitrogen) at an Xbal site. The resulting recombinant expression vector pVLDRADA140 contained the endogenous translation initiation and termination codons as well as the 155 bp 5 ' untranslated sequence and 724 bp 3 ' untranslated sequence of full-length DRADA [SEQ ID NO: 1] . See Fig. 4A. For pVLDRADA140Δ , a new termination codon was created at residue 880 by filling-in the over-hang of the Xmalll located downstream of the dsRNA binding motifs (DRBM) . This procedure replaced the original sequence SEQ ID NO: 37: KILAAIIMKKDSE with a newly created C- terminal sequence, SEQ ID NO: 38: PQDSGHHHYEKRL at residues 867 to 879. See Fig. 4B. Sf9 insect cells were infected with the above- described recombinant baculoviruses. Cells were cultured by conventional means. Protein production was assessed by labeling Spodoptera frugiperdera (Sf9) cells with 50 μCi [ 35 S]methionine for 1 hour [O'Reilly et al, Baculovirus Expression Vectors, W. H. Freeman and Co. , Oxford, England (1992)]. The labeled protein was analyzed by SDS-PAGE and fluorography. A unique band of 140 kD protein was detected in cells infected with the recombinant virus containing the entire coding sequence (DRADA140) indicating that a full length protein was expressed from the recombinant virus. A band of about 110 kD protein was detected in the cells infected with DRADAΔ. The DRADA activity was analyzed in crude extracts made from 4 x 10 7 cells in an assay for detection of modified bases [described previously in Wagner et al, (1990) cited above] illustrating inosine 5 '-monophosphate (pi) and adenosine 5'-monophosphate (pA) for DRADA 140 and DRADA delta, using 20 μg of protein at 37°C for 2 hours. See Example 2. As a reference, crude extracts made from Sf9 cells, as well as HeLa cells, were assayed using increasing amounts (1, 10, 20 and 40 μg) of protein. Only the extracts of the cells expressing DRADA140 showed adenosine to inosine conversion activity at a high level (5 times higher than that of HeLa nuclear extracts, which have previously been shown to contain a relatively high level of the DRADA activity [Wagner et al., (1990), cited above]). In contrast, the cells expressing a DRADAΔ, as well as uninfected Sf9 cells, displayed very little, if any, detectable base modification activity. These results confirm that the cloned cDNA indeed codes for a functional DRADA enzyme. A separate assay tested in non-saturating, linear range (20 μg of protein t 37°C for 30 min with excess of substrate dsRNA) indicated that Sf9 cells infected with DRADA 140 for 41 hours contained approximately 5 times more DRADA activity than HeLa cells. Interestingly, the NH 2 -terminally truncated forms of DRADA, p93 and p88, were not detected in Sf9 cells infected with recombinant virus carrying the entire DRADA ORF (Fig. 2A) . Thus, these N-terminally truncated forms of DRADA appear to be produced by proteolysis during the protein purification. Example 6 - Southern blot Analysis of the DRADA gene The DRADA gene was detected in various species by Southern blot analysis. Briefly, twenty μg of chromosomal DNA was digested with either EcoRI and BamHI or EcoRI and Hindlll, fractionated on an agarose gel (0.9%), and transferred to a Genescreen plus membrane. The membrane was hybridized with 32 P-labeled probe (1.2 kb EcoRI/BamHI fragment of HUCl; 10 16 cpm/mL) in solution containing 2X SSC, IX Denhardt's solution, 40% formamide, 10% dextran sulfate, 1% SDS, and 0.05 mg/ml salmon sperm DNA, at 37°C for 18 hours. The membrane was then washed with one change of 2X SSC at room temperature for 20 min followed by a wash with 2X SSC and 1% SDS at 37°C for 30 minutes. The membrane was exposed at -70°C for 68 hours. The DNA was obtained from HeLa (human) , BFA-1C BPT (bovine) , M0PC11 (mouse) , XTC-2 (Xenopus laevis; amphibian) , and Sf9 (insect) cells. Two recently obtained overlapping human genomic clones were analyzed for restriction site mapping. These results suggest that all DNA bands including the faint ones arise from a single DRADA gene. The Southern blot analysis indicated that the DRADA gene is well conserved in mammalian cells. The genomic DNA prepared from human, mouse, and bovine cells hybridized strongly with the human cDNA probe. However, this probe did not detect sequences in amphibian or insect genomes. Since the enzymatic activity of DRADA has been reported in these two species, additional cDNA probes including a DNA fragment encoding the C-terminal region predicted to contain the conserved catalytic domain were tested. All probes gave negative results. Thus, it is postulated that the DRADA sequence has not been well conserved during evolution, except in certain short stretches possibly involved in catalysis. Example 7 - Northern blot Analysis of Human Tissues Expression of transcripts encoding DRADA was studied by Northern hybridization against mRNA from various human tissues. A Northern blot containing 2 μg of polyA + RNA (Clontech) was hybridized with a human cDNA probe according to the manufacturer's instructions. Briefly, the blot was prehybridized in 5X SSPE, 10X Denhardt's solution, 50% formamide, 2% SDS, and 0.1 mg/ml denatured salmon sperm DNA at 42°C for 4 hours, followed by hybridization in a fresh solution containing the denatured probe at 42°C for 18 hours. The blot was washed with several changes of 2XSSC and 0.05% SDS at room temperature for 30 minutes, then with one change of 0.1X SSC and 0.1% SDS at 50°C for 1 hour. The blot was rehybridized with a glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA control probe. The resulting Northern analysis blot located DRADA transcripts in all tissues tested, including the heart, brain, placenta, lung, liver, muscle, kidney and pancreas. The size of the DRADA mRNA (7 kb) indicates that the overlapping cDNAs (6,671 nucleotides) contain nearly the entire DRADA mRNA. As previously shown by the modified-base assay of crude extracts made from various tissues, the DRADA gene appeared to be expressed ubiquitously. Brain tissue contains a high level of DRADA transcript, consistent with proposed involvement in the RNA editing of glutamate-gated ion-channel transcripts [Sommer et al., Cell, .62:11-19 (1991); Higuchi et al., Cell. 75:1361-1370 (1993)]. Example 8 - Structural Features of DRADA Computer-assisted inspection of the predicted primary structure revealed several features that illuminate the functional properties of DRADA. Fig. 5 illustrates similarities between DRADA and other dsRNA binding proteins. Alignments among different DRBM and deaminases were performed by the PILEUP, BESTFIT and GAP programs. Identification of various protein sequence motifs was performed by the MOTIFS program of the GCG sequence analysis package, version 7.0 [J. Devereux et al, Nucleic Acids Res.. 12:387-395 (1984)]. A. DRADA and dsRNA Interaction The central region of the DRADA protein contains three repeats of a dsRNA binding motif (DRBM; see Figs. 1A - 1J) . The presence of dsRNA binding motifs in DRADA (aa500-700) were first recognized as three internal repeats revealed during computer analysis of DRADA amino acid sequences. The presence of these motifs explains the selectivity of DRADA for duplex RNA and identifies DRADA as a member of a growing family of DRBM containing proteins. This motif was recognized by several different groups in a number of proteins that are presumed to bind dsRNA and to carry out a diverse array of functions such as regulation of development, interaction with HIV, and cleavage of dsRNA. See, e.g., A. Gatignol et al, Mol. Cell. Biol.. 13_:2193 (1993); and D. St. Johnson et al, Proc. Natl. Acad. Sci. USA. £:10979 (1992) among others. For example, the dissociation constant (Kd) of DRADA to a 575 bp dsRNA was 0.23 nM comparable to other RNA binding proteins known to have very high affinity, such as TAT binding to TAR (Kd=0.14 nM) , and rev binding to RRE (Kd = 0.3 nM) of HIV. Each motif is capable of binding independently to dsRNA allowing DRADA to make three contacts with dsRNA, and possibly increasing the affinity for dsRNA in a cooperative manner. It should be pointed out that multiple DRADA seem to bind to the long dsRNA, as binding studies and substrate requirement studies indicate [Nishikura et al, (1991) , cited above] . These proteins carry out a diverse array of functions such as regulation and early development (Staufen) [St. Johnson et al, cited above] and interaction with human immunodeficiency virus RNA (TAR- binding protein) [Gatignol et al, cited above]. Note that there is an additional internal repeat at the position aa200-250 of SEQ ID NO: 2. This is not related to DRBM and appeared to be unique to human DRBM, since this repeat was not present in the bovine DRADA sequence. There is a partial conservation of an RNP core consensus sequence just 62 residues upstream of DRBM-1 (GYVDF, residues 445-449 of SEQ ID NO: 2). The RNP consensus found in many SSRNA binding proteins, such as nucleolin and poly(A)-binding protein [S. R. Haynes, New Biol.. J_:421-429 (1992)], consists of a 90-residue stretch of loosely conserved sequence within which reside highly conserved core sequences of eight (RNP-1) and five (RNP-2) residues. The short RNP-2-like stretch found in DRADA may participate in destabilizing A-U base pairs and in creating a local SSRNA region before adenosine deaminase. In addition to DRBM, the computer analysis of the DRADA sequence by the MOTIFS program (GCG) revealed the presence of a bipartite nuclear localization signal comprising two basic residues followed by ten flanking residues and a basic cluster at residues 169 through 185 of DRADA SEQ ID NO: 2. This is consistent with the finding of the DRADA activity in the biochemically purified nuclear fraction of mammalian cells and tissues. The DRADA sequence contained numerous potential phosphorylation sites hinting that DRADA activity may be regulated by phosphorylation. Furthermore, although the enzyme was originally called "dsRNA unwindase," inspection of DRADA sequence did not show any significant homology to known helicase (DEAD or DEAH proteins) , confirming previous conclusions from biochemical analysis that DRADA does not have any classical helicase activity. Since the biochemically purified 93 and 88 kD proteins, lacking the N-terminal region of the full length protein, exhibit the DRADA activity the amino acid residues directly involved in the catalytic mechanism are expected to reside at the C-terminal region, most likely the downstream of three repeats of DRBM. Note that the C-terminal truncated mutant (DRADAΔ) does not exhibit DRADA activity. Mutagenic analysis of this substrate binding domain of DRADA has been carried out. The deletion of the first or third DRBM within the substrate binding domain consisting of three repeats of the motif, abolishes the enzyme activity, whereas the second motif seems to be dispensible. These results indicate that these three DRBM motifs are not equivalent in their roles in the DRADA activity. B. Catalytic Mechanism of DRADA and Conservation of Residues Required for Deamination A set of evolutionarily conserved amino acid residues arranged and spaced in a specific sequence context has been reported in adenosine deaminase (ADA) and adenosine monophosphate (AMP) deaminases has been reported [Z. Chang et al, Biochem.. 3_0:2273 (1991)], and also for cytidine deaminases and deoxycytidylate (dCMP) . The C-terminal region of DRADA contains the tripeptide sequences HAE and PCG, which are conserved in several cytidine and dCMP deaminases, including SEQ ID NO: 39: REPR [B. Teng et al, Science. 260:1816 (1993)]. (A database search revealed a nematode gene (T20H4.4) of unknown function [Wilson et al, Nature (London) . 368:32- 38 (1994) ] with a considerable degree of sequence conservation to the C-terminal region of DRADA, particularly around the tripeptide HAE and PCG sequences. This nematode gene may encode a prototype of the vertebrate version of DRADA.) REPR is believed to be a subunit of a muIticomponent enzyme containing a specific cytidine deaminase activity responsible for the RNA editing of apolipoprotein B mRNAs. These tripeptides contain histidine, glutamic acid, and cysteine, which are likely to be involved in the coordination of a zinc atom and formation of the catalytic center of DRADA. Mutagenic analysis of this catalytic domain of DRADA was carried out. Mutation of the putative zinc-coordinating residues, His 910 , Cys 966 , and Cys 1036 , abolished DRADA activity. Similarly, the Glu 912 residue, predicted to exert proton transfer functions of the enzyme, was confirmed to be indispensible. This data supports the conclusion that the hydrolytic deamination mechanism of DRADA is similar to that of cytidine deaminases. This data also indicates sites of DRADA which may be modified to extinguish its activity, e.g., in circumstances where excessive DRADA activity is the cause of disease. While certain embodiments of the invention have been particularly described, it will be apparent to those skilled in the art that many modifications and variations may be made. Therefore, the present invention is not to be construed as limited by any of the particular embodiments shown, rather its scope will be defined only by the claims which follow. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Wistar Institute of Anatomy & Biology (ii) TITLE OF INVENTION: RNA Editing Enzyme and Methods of Use Thereof (iii) NUMBER OF SEQUENCES: 39 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Howson and Howson (B) STREET: Spring House Corporate Cntr, P.O. Box 457 (C) CITY: Spring House (D) STATE: Pennsylvania (E) COUNTRY: USA (F) ZIP: 19477 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/280,443 (B) FILING DATE: 25-JUL-1994 (Vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/197,794 (B) FILING DATE: 17-FEB-1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Bak, Mary E. (B) REGISTRATION NUMBER: 31,215 (C) REFERENCE/DOCKET NUMBER: WST49BPCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 215-540-9206 (B) TELEFAX: 215-540-5818 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6671 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 155..3832 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CGCAGACCCG CGGAGTTTCC CGTGCCGACG CCCCGGGGCC ACTTCCAGTG 50 CGGAGTAGCG GAGGCGTGGG GGCCTCGAGG GGCTGGCGCG GTCCAGCGGT 100 CGGGCCAGGG TCGTGCCGCC GGCGGGTCGG GCCGGACAAT GCCTCGCGGG 150 CGCA ATG AAT CCG CGG CAG GGG TAT TCC CTC AGC GGA TAC TAC 193 Met Asn Pro Arg Gin Gly Tyr Ser Leu Ser Gly Tyr Tyr 1 5 10 ACC CAT CCA TTT CAA GGC TAT GAG CAC AGA CAG CTC AGA TAC 235 Thr His Pro Phe Gin Gly Tyr Glu His Arg Gin Leu Arg Tyr 15 20 25 CAG CAG CCT GGG CCA GGA TCT TCC CCC AGT AGT TTC CTG CTT 277 Gin Gin Pro Gly Pro Gly Ser Ser Pro Ser Ser Phe Leu Leu 30 35 40 AAG CAA ATA GAA TTT CTC AAG GGG CAG CTC CCA GAA GCA CCG 319 Lys Gin lie Glu Phe Leu Lys Gly Gin Leu Pro Glu Ala Pro 45 50 55 GTG ATT GGA AAG CAG ACA CCG TCA CTG CCA CCT TCC CTC CCA 361 Val lie Gly Lys Gin Thr Pro Ser Leu Pro Pro Ser Leu Pro 60 65 GGA CTC CGG CCA AGG TTT CCA GTA CTA CTT GCC TCC AGT ACC 403 Gly Leu Arg Pro Arg Phe Pro Val Leu Leu Ala Ser Ser Thr 70 75 80 AGA GGC AGG CAA GTG GAC ATC AGG GGT GTC CCC AGG GGC GTG 445 Arg Gly Arg Gin Val Asp lie Arg Gly Val Pro Arg Gly Val 85 90 95 CAT CTC GGA AGT CAG GGG CTC CAG AGA GGG TTC CAG CAT CCT 487 His Leu Gly Ser Gin Gly Leu Gin Arg Gly Phe Gin His Pro 100 105 110 TCA CCA CGT GGC AGG AGT CTG CCA CAG AGA GGT GTT GAT TGC 529 Ser Pro Arg Gly Arg Ser Leu Pro Gin Arg Gly Val Asp Cys 115 120 125 CTT TCC TCA CAT TTC CAG GAA CTG AGT ATC TAC CAA GAT CAG 571 Leu Ser Ser His Phe Gin Glu Leu Ser lie Tyr Gin Asp Gin 130 135 GAA CAA AGG ATC TTA AAG TTC CTG GAA GAG CTT GGG GAA GGG 613 Glu Gin Arg lie Leu Lys Phe Leu Glu Glu Leu Gly Glu Gly 140 145 150 AAG GCC ACC ACA GCA CAT GAT CTG TCT GGG AAA CTT GGG ACT 655 Lys Ala Thr Thr Ala His Asp Leu Ser Gly Lys Leu Gly Thr 155 160 165 CCG AAG AAA GAA ATC AAT CGA GTT TTA TAC TCC CTG GCA AAG 697 Pro Lys Lys Glu lie Asn Arg Val Leu Tyr Ser Leu Ala Lys 170 175 180 AAG GGC AAG CTA CAG AAA GAG GCA GGA ACA CCC CCT TTG TGG 739 Lys Gly Lys Leu Gin Lys Glu Ala Gly Thr Pro Pro Leu Trp 185 190 195 AAA ATC GCG GTC TCC ACT CAG GCT TGG AAC CAG CAC AGC GGA 781 Lys lie Ala Val Ser Thr Gin Ala Trp Asn Gin His Ser Gly 200 205 GTG GTA AGA CCA GAC GGT CAT AGC CAA GGA GCC CCA AAC TCA 823 Val Val Arg Pro Asp Gly His Ser Gin Gly Ala Pro Asn Ser 210 215 220 GAC CCG AGT TTG GAA CCG GAA GAC AGA AAC TCC ACA TCT GTC 865 Asp Pro Ser Leu Glu Pro Glu Asp Arg Asn Ser Thr Ser Val 225 230 235 TCA GAA GAT CTT CTT GAG CCT TTT ATT GCA GTC TCA GCT CAG 907 Ser Glu Asp Leu Leu Glu Pro Phe lie Ala Val Ser Ala Gin 240 245 250 GCT TGG AAC CAG CAC AGC GGA GTG GTA AGA CCA GAC AGT CAT 949 Ala Trp Asn Gin His Ser Gly Val Val Arg Pro Asp Ser His 255 260 265 AGC CAA GGA TCC CCA AAC TCA GAC CCA GGT TTG GAA CCT GAA 991 Ser Gin Gly Ser Pro Asn Ser Asp Pro Gly Leu Glu Pro Glu 270 275 GAC AGC AAC TCC ACA TCT GCC TTG GAA GAT CCT CTT GAG TTT 1033 Asp Ser Asn Ser Thr Ser Ala Leu Glu Asp Pro Leu Glu Phe 280 285 290 TTA GAC ATG GCC GAG ATC AAG GAG AAA ATC TGC GAC TAT CTC 1075 Leu Asp Met Ala Glu lie Lys Glu Lys lie Cys Asp Tyr Leu 295 300 305 TTC AAT GTG TCT GAC TCC TCT GCC CTG AAT TTG GCT AAA AAT 1117 Phe Asn Val Ser Asp Ser Ser Ala Leu Asn Leu Ala Lys Asn 310 315 320 ATT GGC CTT ACC AAG GCC CGA GAT ATA AAT GCT GTG CTA ATT 1159 lie Gly Leu Thr Lys Ala Arg Asp lie Asn Ala Val Leu lie 325 330 335 GAC ATG GAA AGG CAG GGG GAT GTC TAT AGA CAA GGG ACA ACC 1201 Asp Met Glu Arg Gin Gly Asp Val Tyr Arg Gin Gly Thr Thr 340 345 CCT CCC ATA TGG CAT TTG ACA GAC AAG AAG CGA GAG AGG ATG 1243 Pro Pro lie Trp His Leu Thr Asp Lys Lys Arg Glu Arg Met 350 355 360 CAA ATC AAG AGA AAT ACG AAC AGT GTT CCT GAA ACC GCT CCA 1285 Gin lie Lys Arg Asn Thr Asn Ser Val Pro Glu Thr Ala Pro 365 370 375 GCT GCA ATC CCT GAG ACC AAA AGA AAC GCA GAG TTC CTC ACC 1327 Ala Ala lie Pro Glu Thr Lys Arg Asn Ala Glu Phe Leu Thr 380 385 390 TGT AAT ATA CCC ACA TCA AAT GCC TCA AAT AAC ATG GTA ACC 1369 Cys Asn lie Pro Thr Ser Asn Ala Ser Asn Asn Met Val Thr 395 400 405 ACA GAA AAA GTG GAG AAT GGG CAG GAA CCT GTC ATA AAG TTA 1411 Thr Glu Lys Val Glu Asn Gly Gin Glu Pro Val lie Lys Leu 410 415 GAA AAC AGG CAA GAG GCC AGA CCA GAA CCA GCA AGA CTG AAA 1453 Glu Asn Arg Gin Glu Ala Arg Pro Glu Pro Ala Arg Leu Lys 420 425 430 CCA CCT GTT CAT TAC AAT GGC CCC TCA AAA GCA GGG TAT GTT 1495 Pro Pro Val His Tyr Asn Gly Pro Ser Lys Ala Gly Tyr Val 435 440 445 GAC TTT GAA AAT GGC CAG TGG GCC ACA GAT GAC ATC CCA GAT 1537 Asp Phe Glu Asn Gly Gin Trp Ala Thr Asp Asp lie Pro Asp 450 455 460 GAC TTG AAT AGT ATC CGC GCA GCA CCA GGT GAG TTT CGA GCC 1579 Asp Leu Asn Ser lie Arg Ala Ala Pro Gly Glu Phe Arg Ala 465 470 475 ATC ATG GAG ATG CCC TCC TTC TAC AGT CAT GGC TTG CCA CGG 1621 lie Met Glu Met Pro Ser Phe Tyr Ser His Gly Leu Pro Arg 480 485 TGT TCA CCC TAC AAG AAA CTG ACA GAG TGC CAG CTG AAG AAC 1663 Cys Ser Pro Tyr Lys Lys Leu Thr Glu Cys Gin Leu Lys Asn 490 495 500 CCC ATC AGC GGG CTG TTA GAA TAT GCC CAG TTC GCT AGT CAA 1705 Pro lie Ser Gly Leu Leu Glu Tyr Ala Gin Phe Ala Ser Gin 505 510 515 ACC TGT GAG TTC AAC ATG ATA GAG CAG AGT GGA CCA CCC CAT 1747 Thr Cys Glu Phe Asn Met lie Glu Gin Ser Gly Pro Pro His 520 525 530 GAA CCT CGA TTT AAA TTC CAG GTT GTC ATC AAT GGC CGA GAG 1789 Glu Pro Arg Phe Lys Phe Gin Val Val lie Asn Gly Arg Glu 535 540 545 TTT CCC CCA GCT GAA GCT GGA AGC AAG AAA GTG GCC AAG CAG 1831 Phe Pro Pro Ala Glu Ala Gly Ser Lys Lys Val Ala Lys Gin 550 555 GAT GCA GCT ATG AAA GCC ATG ACA ATT CTG CTA GAG GAA GCC 1873 Asp Ala Ala Met Lys Ala Met Thr lie Leu Leu Glu Glu Ala 560 565 570 AAA GCC AAG GAC AGT GGA AAA TCA GAA GAA TCA TCC CAC TAT 1915 Lys Ala Lys Asp Ser Gly Lys Ser Glu Glu Ser Ser His Tyr 575 580 585 TCC ACA GAG AAA GAA TCA GAG AAG ACT GCA GAG TCC CAG ACC 1957 Ser Thr Glu Lys Glu Ser Glu Lys Thr Ala Glu Ser Gin Thr 590 595 600 CCC ACC CCT TCA GCC ACA TCC TTC TTT TCT GGG AAG AGC CCC 1999 Pro Thr Pro Ser Ala Thr Ser Phe Phe Ser Gly Lys Ser Pro 605 610 615 GTC ACC ACA CTG CTT GAG TGT ATG CAC AAA TTG GGG AAC TCC 2041 Val Thr Thr Leu Leu Glu Cys Met His Lys Leu Gly Asn Ser 620 625 TGC GAA TTC CGT CTC CTG TCC AAA GAA GGC CCT GCC CAT GAA 2083 Cys Glu Phe Arg Leu Leu Ser Lys Glu Gly Pro Ala His Glu 630 635 640 CCC AAG TTC CAA TAC TGT GTT GCA GTG GGA GCC CAA ACT TTC 2125 Pro Lys Phe Gin Tyr Cys Val Ala Val Gly Ala Gin Thr Phe 645 650 655 CCC AGT GTG AGT GCT CCC AGC AAG AAA GTG GCA AAG CAG ATG 2167 Pro Ser Val Ser Ala Pro Ser Lys Lys Val Ala Lys Gin Met 660 665 670 GCC GCA GAG GAA GCC ATG AAG GCC CTG CAT GGG GAG GCG ACC 2209 Ala Ala Glu Glu Ala Met Lys Ala Leu His Gly Glu Ala Thr 675 680 685 AAC TCC ATG GCT TCT GAT AAC CAG CCT GAA GGT ATG ATC TCA 2251 Asn Ser Met Ala Ser Asp Asn Gin Pro Glu Gly Met lie Ser 690 695 GAG TCA CTT GAT AAC TTG GAA TCC ATG ATG CCC AAC AAG GTC 2293 Glu Ser Leu Asp Asn Leu Glu Ser Met Met Pro Asn Lys Val 700 705 710 AGG AAG ATT GGC GAG CTC GTG AGA TAC CTG AAC ACC AAC CCT 2335 Arg Lys lie Gly Glu Leu Val Arg Tyr Leu Asn Thr Asn Pro 715 720 725 GTG GGT GGC CTT TTG GAG TAC GCC CGC TCC CAT GGC TTT GCT 2377 Val Gly Gly Leu Leu Glu Tyr Ala Arg Ser His Gly Phe Ala 730 735 740 GCT GAA TTC AAG TTG GTC GAC CAG TCC GGA CCT CCT CAC GAG 2419 Ala Glu Phe Lys Leu Val Asp Gin Ser Gly Pro Pro His Glu 745 750 755 CCC AAG TTC GTT TAC CAA GCA AAA GTT GGG GGT CGC TGG TTC 2461 Pro Lys Phe Val Tyr Gin Ala Lys Val Gly Gly Arg Trp Phe 760 765 CCA GCC GTC TGC GCA CAC AGC AAG AAG CAA GGC AAG CAG GAA 2503 Pro Ala Val Cys Ala His Ser Lys Lys Gin Gly Lys Gin Glu 770 775 780 GCA GCA GAT GCG GCT CTC CGT GTC TTG ATT GGG GAG AAC GAG 2545 Ala Ala Asp Ala Ala Leu Arg Val Leu lie Gly Glu Asn Glu 785 790 795 AAG GCA GAA CGC ATG GGT TTC ACA GAG GTA ACC CCA GTG ACA 2587 Lys Ala Glu Arg Met Gly Phe Thr Glu Val Thr Pro Val Thr 800 805 810 GGG GCC AGT CTC AGA AGA ACT ATG CTC CTC CTC TCA AGG TCC 2629 Gly Ala Ser Leu Arg Arg Thr Met Leu Leu Leu Ser Arg Ser 815 820 825 CCA GAA GCA CAG CCA AAG ACA CTC CCT CTC ACT GGC AGC ACC 2671 Pro Glu Ala Gin Pro Lys Thr Leu Pro Leu Thr Gly Ser Thr 830 835 TTC CAT GAC CAG ATA GCC ATG CTG AGC CAC CGG TGC TTC AAC 2713 Phe His Asp Gin lie Ala Met Leu Ser His Arg Cys Phe Asn 840 845 850 ACT CTG ACT AAC AGC TTC CAG CCC TCC TTG CTC GGC CGC AAG 2755 Thr Leu Thr Asn Ser Phe Gin Pro Ser Leu Leu Gly Arg Lys 855 860 865 ATT CTG GCC GCC ATC ATT ATG AAA AAA GAC TCT GAG GAC ATG 2797 lie Leu Ala Ala lie lie Met Lys Lys Asp Ser Glu Asp Met 870 875 880 GGT GTC GTC GTC AGC TTG GGA ACA GGG AAT CGC TGT GTG AAA 2839 Gly Val Val Val Ser Leu Gly Thr Gly Asn Arg Cys Val Lys 885 890 895 GGA GAT TCT CTC AGC CTA AAA GGA GAA ACT GTC AAT GAC TGC 2881 Gly Asp Ser Leu Ser Leu Lys Gly Glu Thr Val Asn Asp Cys 900 905 CAT GCA GAA ATA ATC TCC CGG AGA GGC TTC ATC AGG TTT CTC 2923 His Ala Glu lie lie Ser Arg Arg Gly Phe lie Arg Phe Leu 910 915 920 TAC AGT GAG TTA ATG AAA TAC AAC TCC CAG ACT GCG AAG GAT 2965 Tyr Ser Glu Leu Met Lys Tyr Asn Ser Gin Thr Ala Lys Asp 925 930 935 AGT ATA TTT GAA CCT GCT AAG GGA GGA GAA AAG CTC CAA ATA 3007 Ser lie Phe Glu Pro Ala Lys Gly Gly Glu Lys Leu Gin lie 940 945 950 AAA AAG ACT GTG TCA TTC CAT CTG TAT ATC AGC ACT GCT CCG 3049 Lys Lys Thr Val Ser Phe His Leu Tyr lie Ser Thr Ala Pro 955 960 965 TGT GGA GAT GGC GCC CTC TTT GAC AAG TCC TGC AGC GAC CGT 3091 Cys Gly Asp Gly Ala Leu Phe Asp Lys Ser Cys Ser Asp Arg 970 975 GCT ATG GAA AGC ACA GAA TCC CGC CAC TAC CCT GTC TTC GAG 3133 Ala Met Glu Ser Thr Glu Ser Arg His Tyr Pro Val Phe Glu 980 985 990 AAT CCC AAA CAA GGA AAG CTC CGC ACC AAG GTG GAG AAC GGA 3175 Asn Pro Lys Gin Gly Lys Leu Arg Thr Lys Val Glu Asn Gly 995 1000 1005 GAA GGC ACA ATC CCT GTG GAA TCC AGT GAC ATT GTG CCT ACG 3217 Glu Gly Thr lie Pro Val Glu Ser Ser Asp lie Val Pro Thr 1010 1015 1020 TGG GAT GGC ATT CGG CTC GGG GAG AGA CTC CGT ACC ATG TCC 3259 Trp Asp Gly lie Arg Leu Gly Glu Arg Leu Arg Thr Met Ser 1025 1030 1035 TGT AGT GAC AAA ATC CTA CGC TGG AAC GTG CTG GGC CTG CAA 3301 Cys Ser Asp Lys lie Leu Arg Trp Asn Val Leu Gly Leu Gin 1040 1045 GGG GCA CTG TTG ACC CAC TTC CTG CAG CCC ATT TAT CTC AAA 3343 Gly Ala Leu Leu Thr His Phe Leu Gin Pro lie Tyr Leu Lys 1050 1055 1060 TCT GTC ACA TTG GGT TAC CTT TTC AGC CAA GGG CAT CTG ACC 3385 Ser Val Thr Leu Gly Tyr Leu Phe Ser Gin Gly His Leu Thr 1065 1070 1075 CGT GCT ATT TGC TGT CGT GTG ACA AGA GAT GGG AGT GCA TTT 3427 Arg Ala lie Cys Cys Arg Val Thr Arg Asp Gly Ser Ala Phe 1080 1085 1090 GAG GAT GGA CTA CGA CAT CCC TTT ATT GTC AAC CAC CCC AAG 3469 Glu Asp Gly Leu Arg His Pro Phe lie Val Asn His Pro Lys 1095 1100 1105 GTT GGC AGA GTC AGC ATA TAT GAT TCC AAA AGG CAA TCC GGG 3511 Val Gly Arg Val Ser lie Tyr Asp Ser Lys Arg Gin Ser Gly 1110 1115 AAG ACT AAG GAG ACA AGC GTC AAC TGG TGT CTG GCT GAT GGC 3553 Lys Thr Lys Glu Thr Ser Val Asn Trp Cys Leu Ala Asp Gly 1120 1125 1130 TAT GAC CTG GAG ATC CTG GAC GGT ACC AGA GGC ACT GTG GAT 3595 Tyr Asp Leu Glu lie Leu Asp Gly Thr Arg Gly Thr Val Asp 1135 1140 1145 GGG CCA CGG AAT GAA TTG TCC CGG GTC TCC AAA AAG AAC ATT 3637 Gly Pro Arg Asn Glu Leu Ser Arg Val Ser Lys Lys Asn lie 1150 1155 1160 TTT CTT CTA TTT AAG AAG CTC TGC TCC TTC CGT TAC CGC AGG 3679 Phe Leu Leu Phe Lys Lys Leu Cys Ser Phe Arg Tyr Arg Arg 1165 1170 1175 GAT CTA CTG AGA CTC TCC TAT GGT GAG GCC AAG AAA GCT GCC 3721 Asp Leu Leu Arg Leu Ser Tyr Gly Glu Ala Lys Lys Ala Ala 1180 1185 CGT GAC TAC GAG ACG GCC AAG AAC TAC TTC AAA AAA GGC CTG 3763 Arg Asp Tyr Glu Thr Ala Lys Asn Tyr Phe Lys Lys Gly Leu 1190 1195 1200 AAG GAT ATG GGC TAT GGG AAC TGG ATT AGC AAA CCC CAG GAG 3805 Lys Asp Met Gly Tyr Gly Asn Trp lie Ser Lys Pro Gin Glu 1205 1210 1215 GAA AAG AAC TTT TAT CTC TGC CCA GTA TAGTATGCTC 3842 Phe Tyr Glu Lys Asn Leu Cys Pro Val 1220 1225 CAGTGACAGA TGGATTAGGG TGTGTCATAC TAGGGTGTGA GAGAGGTAGG 3892 TCGTAGCATT CCTCATCACA TGGTCAGGGG ATTTTTTTTT CTCCTTTTTT 3942 TTTTCTTTTT AAGCCATAAT TGGTGATACT GAAAACTTTG GGTTCCCATT 3992 TATCCTGCTT TCTTTGGGAT TGCTAGGCAA GGTCTGGCCA GGCCCCCCTT 4042 TTTTCCCCCA AGTGAAGAGG CAGAAACCTA AGAAGTTATC TTTTCTTTCT 4092 ACCCAAAGCA TACATAGTCA CTGAGCACCT GCGGTCCATT TCCTCTTAAA 4142 AGTTTTGTTT TGATTTGTTT CCATTTCCTT TCCCTTTGTG TTTGCTACAC 4192 TGACCTCTTG CGGTCTTGAT TAGGTTTCAG TCAACTCTGG ATCATGTCAG 4242 GGACTGATAA TTTCATTTGT GGATTACGCA GACCCCTCTA CTTCCCCTCT 4292 TTCCCTTCTG AGATTCTTTC CTTGTGATCT GAATGTCTCC TTTTCCCCCT 4342 CAGAGGGCAA AGAGGTGAAC ATAAAGGATT TGGTGAAACA TTTGTAAGGG 4392 TAGGAGTTGA AAACTGCAGT TCCCAGTGCC ACGGAAGTGT GATTGGAGCC 4442 TGCAGATAAT GCCCAGCCAT CCTCCCATCC TGCACTTTAG CCAGCTGCAG 4492 GGCGGGCAAG GCAAGGAAAG CTGCTTCCCT GGAAGTGTAT CACTTTCTCC 4542 GGCAGCTGGG AAGTCTAGAA CCAGCCAGAC TGGGTTAAGG GAGCTGCTCA 4592 AGCAATAGCA GAGGTTTCAC CCGGCAGGAT GACACAGACC ACTTCCCAGG 4642 GAGCACGGGC ATGCCTTGGA ATATTGCCAA GCTTCCAGCT GCCTCTTCTC 4692 CTAAAGCATT CCTAGGAATA TTTTCCCCGC CAATGCTGGG CGTACACCCT 4742 AGCCAACGGG ACAAATCCTA GAGGGTATAA AATCATCTCT GCTCAGATAA 4792 TCATGACTTA GCAAGAATAA GGGCAAAAAA TCCTGTTGGC TTAACGTCAC 4842 TGTTCCACCC GGTGTAATAT CTCTCATGAC AGTGACACCA AGGGAAGTTG 4892 ACTAAGTCAC ATGTAAATTA GGAGTGTTTT AAAGAATGCC ATAGATGTTG 4942 ATTCTTAACT GCTACAGATA ACCTGTAATT GAGCAGATTT AAAATTCAGG 4992 CATACTTTTC CATTTATCCA AGTGCTTTCA TTTTTCCAGA TGGCTTCAGA 5042 AGTAGGCTCG TGGGCAGGGC GCAGACCTGA TCTTTATAGG GTTGACATAG 5092 AAAGCAGTAG TTGTGGGTGA AAGGGCAGGT TGTCTTCAAA CTCTGTGAGG 5142 TAGAATCCTT TGTCTATACC TCCATGAACA TTGACTCGTG TGTTCAGAGC 5192 CTTTGGCCTC TCTGTGGAGT CTGGCTCTCT GGCTCCTGTG CATTCTTTGA 5242 ATAGTCACTC GTAAAAACTG TCAGTGCTTG AAACTGTTTC CTTTACTCAT 5292 GTTGAAGGGA CTTTGTTGGC TTTTAGAGTG TTGGTCATGA CTCCAAGAGC 5342 AGAGCAGGGA AGAGCCCAAG CATAGACTTG GTGCCGTGGT GATGGCTGCA 5392 GTCCAGTTTT GTGATGCTGC TTTTACGTGT CCCTCGATAA CAGTCAGCTA 5442 GACACACTCA GGAGGACTAC TGAGGCTCTG CGACCTTCAG GAGCTGAGCC 5492 TGCCTCTCTC CTTTAGATGA CAGACCTTCA TCTGGGAACG TGCTGAGCCA 5542 GCACCCTCAG ATGATTTCCC TCCAAACTGC TGACTAGGTC ATCCTCTGTC 5592 TGGTAGAGAC ATTCACATCT TTGCTTTTAT TCTATGCTCT CTGTACTTTT 5642 GACCAAAAAT TGACCAAAGT AAGAAAATGC AAGTTCTAAA AATAGACTAA 5692 GGATGCCTTT GCAGAACACC AAAGCATCCC AAGGAACTGG TAGGGAAGTG 5742 GCGCCTGTCT CCTGGAGTGG AAGAGGCCTG CTCCCTGCTC TGGGTCTGCT 5792 GGGGGCACAG TAAATCAGTC TTGGCACCCA CATCCAGGGC AGAGAGGTCT 5842 GTGGTTCTCA GCATCAGAAG GCAGCGCAGC CCCTCTCCTC TTCAGGCTAC 5892 AGGGTTGTCA CCTGCTGAGT CCTCAGGTTG TTTGGCCTCT CTGGTCCATC 5942 TTGGGCATTA GGTTCTCCAG CAGAGCTCTG GCCAGCTGCC TCTTCTTTAA 5992 CTGGGAACAC AGGCTCTCAC AAGATCAGAA CCCCCACTCA CCCCCAAGAT 6042 CTTATCTAGC AAGCCTGTAG TATTCAGTTT CTGTTGTAGG AAGAGAGCGA 6092 GGCATCCCTG AATTCCACGC ATCTGCTGGA AACGAGCCGT GTCAGATCGC 6142 ACATCCCTGC GCCCCCATGC CCCTCTGAGT CACACAGGAC AGAGGAGGCA 6192 GAGCTTCTGC CCACTGTTAT CTTCACTTTC TTTGTCCAGT CTTTTGTTTT 6242 TAATAAGCAG TGACCCTCCC TACTCTTCTT TTTAATGATT TTTGTAGTTG 6292 ATTTGTCTGA ACTGTGGCTA CTGTGCATTC CTTGAATAAT CACTTGTAAA 6342 AATTGTCAGT GCTTGAAGCT GTTTCCTTTA CTCACATTGA AGGGACTTCG 6392 TTGGTTTTTT GGAGTCTTGG TTGTGACTCC AAGAGCAGAG TGAGGAAGAC 6442 CCCCAAGCAT AGACTCGGGT ACTGTGATGA TGGCTGCAGT CCAGTTTTAT 6492 GATTCTGCTT TTATGTGTCC CTTGATAACA GTGACTTAAC AATATACATT 6542 CCTCATAAAT AAAAAAAAAA CAAGAATCTG AAAAAAAAAA AAAAAAAAAA 6592 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 6642 AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 6671 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1226 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Asn Pro Arg Gin Gly Tyr Ser Leu Ser Gly Tyr Tyr Thr His 1 5 10 15 Pro Phe Gin Gly Tyr Glu His Arg Gin Leu Arg Tyr Gin Gin Pro 20 25 30 Gly Pro Gly Ser Ser Pro Ser Ser Phe Leu Leu Lys Gin lie Glu 35 40 45 Phe Leu Lys Gly Gin Leu Pro Glu Ala Pro Val lie Gly Lys Gin 50 55 60 Thr Pro Ser Leu Pro Pro Ser Leu Pro Gly Leu Arg Pro Arg Phe 65 70 75 Pro Val Leu Leu Ala Ser Ser Thr Arg Gly Arg Gin Val Asp lie 80 85 90 Arg Gly Val Pro Arg Gly Val His Leu Gly Ser Gin Gly Leu Gin 95 100 105 Arg Gly Phe Gin His Pro Ser Pro Arg Gly Arg Ser Leu Pro Gin 110 115 120 Arg Gly Val Asp Cys Leu Ser Ser His Phe Gin Glu Leu Ser lie 125 130 135 Tyr Gin Asp Gin Glu Gin Arg lie Leu Lys Phe Leu Glu Glu Leu 140 145 150 Gly Glu Gly Lys Ala Thr Thr Ala His Asp Leu Ser Gly Lys Leu 155 160 165 Gly Thr Pro Lys Lys Glu lie Asn Arg Val Leu Tyr Ser Leu Ala 170 175 180 Lys Lys Gly Lys Leu Gin Lys Glu Ala Gly Thr Pro Pro Leu Trp 185 190 195 Lys lie Ala Val Ser Thr Gin Ala Trp Asn Gin His Ser Gly Val 200 205 210 Val Arg Pro Asp Gly His Ser Gin Gly Ala Pro Asn Ser Asp Pro 215 220 225 Ser Leu Glu Pro Glu Asp Arg Asn Ser Thr Ser Val Ser Glu Asp 230 235 240 Leu Leu Glu Pro Phe lie Ala Val Ser Ala Gin Ala Trp Asn Gin 245 250 255 His Ser Gly Val Val Arg Pro Asp Ser His Ser Gin Gly Ser Pro 260 265 270 Asn Ser Asp Pro Gly Leu Glu Pro Glu Asp Ser Asn Ser Thr Ser 275 280 285 Ala Leu Glu Asp Pro Leu Glu Phe Leu Asp Met Ala Glu lie Lys 290 295 300 Glu Lys lie Cys Asp Tyr Leu Phe Asn Val Ser Asp Ser Ser Ala 305 310 315 Leu Asn Leu Ala Lys Asn lie Gly Leu Thr Lys Ala Arg Asp lie 320 325 330 Ash Ala Val Leu lie Asp Met Glu Arg Gin Gly Asp Val Tyr Arg 335 340 345 Gin Gly Thr Thr Pro Pro lie Trp His Leu Thr Asp Lys Lys Arg 350 355 360 Glu Arg Met Gin lie Lys Arg Asn Thr Asn Ser Val Pro Glu Thr 365 370 375 Ala Pro Ala Ala lie Pro Glu Thr Lys Arg Asn Ala Glu Phe Leu 380 385 390 Thr Cys Asn lie Pro Thr Ser Asn Ala Ser Asn Asn Met Val Thr 395 400 405 Thr Glu Lys Val Glu Asn Gly Gin Glu Pro Val lie Lys Leu Glu 410 415 420 Asn Arg Gin Glu Ala Arg Pro Glu Pro Ala Arg Leu Lys Pro Pro 425 430 435 Val His Tyr Asn Gly Pro Ser Lys Ala Gly Tyr Val Asp Phe Glu 440 445 450 Asn Gly Gin Trp Ala Thr Asp Asp lie Pro Asp Asp Leu Asn Ser 455 460 465 lie Arg Ala Ala Pro Gly Glu Phe Arg Ala lie Met Glu Met Pro 470 475 480 Ser Phe Tyr Ser His Gly Leu Pro Arg Cys Ser Pro Tyr Lys Lys 485 490 495 Leu Thr Glu Cys Gin Leu Lys Asn Pro lie Ser Gly Leu Leu Glu 500 505 510 Tyr Ala Gin Phe Ala Ser Gin Thr Cys Glu Phe Asn Met lie Glu 515 520 525 Gin Ser Gly Pro Pro His Glu Pro Arg Phe Lys Phe Gin Val Val 530 535 540 lie Asn Gly Arg Glu Phe Pro Pro Ala Glu Ala Gly Ser Lys Lys 545 550 555 Val Ala Lys Gin Asp Ala Ala Met Lys Ala Met Thr lie Leu Leu 560 565 570 Glu Glu Ala Lys Ala Lys Asp Ser Gly Lys Ser Glu Glu Ser Ser 575 580 585 His Tyr Ser Thr Glu Lys Glu Ser Glu Lys Thr Ala Glu Ser Gin 590 595 600 Thr Pro Thr Pro Ser Ala Thr Ser Phe Phe Ser Gly Lys Ser Pro 605 610 615 Val Thr Thr Leu Leu Glu Cys Met His Lys Leu Gly Asn Ser Cys 620 625 630 Glu Phe Arg Leu Leu Ser Lys Glu Gly Pro Ala His Glu Pro Lys 635 640 645 Phe Gin Tyr Cys Val Ala Val Gly Ala Gin Thr Phe Pro Ser Val 650 655 660 Ser Ala Pro Ser Lys Lys Val Ala Lys Gin Met Ala Ala Glu Glu 665 670 675 Ala Met Lys Ala Leu His Gly Glu Ala Thr Asn Ser Met Ala Ser 680 685 690 Asp Asn Gin Pro Glu Gly Met lie Ser Glu Ser Leu Asp Asn Leu 695 700 705 Glu Ser Met Met Pro Asn Lys Val Arg Lys lie Gly Glu Leu Val 710 715 720 Arg Tyr Leu Asn Thr Asn Pro Val Gly Gly Leu Leu Glu Tyr Ala 725 730 735 Arg Ser His Gly Phe Ala Ala Glu Phe Lys Leu Val Asp Gin Ser 740 745 750 Gly Pro Pro His Glu Pro Lys Phe Val Tyr Gin Ala Lys Val Gly 755 760 765 Gly Arg Trp Phe Pro Ala Val Cys Ala His Ser Lys Lys Gin Gly 770 775 780 Lys Gin Glu Ala Ala Asp Ala Ala Leu Arg Val Leu lie Gly Glu 785 790 795 Asn Glu Lys Ala Glu Arg Met Gly Phe Thr Glu Val Thr Pro Val 800 805 810 Thr Gly Ala Ser Leu Arg Arg Thr Met Leu Leu Leu Ser Arg Ser 815 820 825 Pro Glu Ala Gin Pro Lys Thr Leu Pro Leu Thr Gly Ser Thr Phe 830 835 840 His Asp Gin lie Ala Met Leu Ser His Arg Cys Phe Asn Thr Leu 845 850 855 Thr Asn Ser Phe Gin Pro Ser Leu Leu Gly Arg Lys lie Leu Ala 860 865 870 Ala lie lie Met Lys Lys Asp Ser Glu Asp Met Gly Val Val Val 875 880 885 Ser Leu Gly Thr Gly Asn Arg Cys Val Lys Gly Asp Ser Leu Ser 890 895 900 Leu Lys Gly Glu Thr Val Asn Asp Cys His Ala Glu lie lie Ser 905 " 910 915 Arg Arg Gly Phe lie Arg Phe Leu Tyr Ser Glu Leu Met Lys Tyr 920 925 930 Asn Ser Gin Thr Ala Lys Asp Ser lie Phe Glu Pro Ala Lys Gly 935 940 945 Gly Glu Lys Leu Gin lie Lys Lys Thr Val Ser Phe His Leu Tyr 950 955 960 lie Ser Thr Ala Pro Cys Gly Asp Gly Ala Leu Phe Asp Lys Ser 965 970 975 Cys Ser Asp Arg Ala Met Glu Ser Thr Glu Ser Arg His Tyr Pro 980 985 990 Val Phe Glu Asn Pro Lys Gin Gly Lys Leu Arg Thr Lys Val Glu 995 1000 1005 Asn Gly Glu Gly Thr lie Pro Val Glu Ser Ser Asp lie Val Pro 1010 1015 1020 Thr Trp Asp Gly lie Arg Leu Gly Glu Arg Leu Arg Thr Met Ser 1025 1030 1035 Cys Ser Asp Lys lie Leu Arg Trp Asn Val Leu Gly Leu Gin Gly 1040 1045 1050 Ala Leu Leu Thr His Phe Leu Gin Pro lie Tyr Leu Lys Ser Val 1055 1060 1065 Thr Leu Gly Tyr Leu Phe Ser Gin Gly His Leu Thr Arg Ala lie 1070 1075 1080 Cys Cys Arg Val Thr Arg Asp Gly Ser Ala Phe Glu Asp Gly Leu 1085 1090 1095 Arg His Pro Phe lie Val Asn His Pro Lys Val Gly Arg Val Ser 1100 1105 1110 lie Tyr Asp Ser Lys Arg Gin Ser Gly Lys Thr Lys Glu Thr Ser 1115 1120 1125 Val Asn Trp Cys Leu Ala Asp Gly Tyr Asp Leu Glu lie Leu Asp * 1130 1135 1140 Gly Thr Arg Gly Thr Val Asp Gly Pro Arg Asn Glu Leu Ser Arg 1145 1150 1155 Val Ser Lys Lys Asn lie Phe Leu Leu Phe Lys Lys Leu Cys Ser 1160 1165 1170 Phe Arg Tyr Arg Arg Asp Leu Leu Arg Leu Ser Tyr Gly Glu Ala 1175 1180 1185 Lys Lys Ala Ala Arg Asp Tyr Glu Thr Ala Lys Asn Tyr Phe Lys 1190 1195 1200 Lys Gly Leu Lys Asp Met Gly Tyr Gly Asn Trp lie Ser Lys Pro 1205 1210 1215 Gin Glu Glu Lys Asn Phe Tyr Leu Cys Pro Val 1220 1225 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Lys Asn Pro lie Ser Gly Leu Leu Glu Tyr Ala Gin Phe Ala Ser 1 5 10 15 Gin Thr Cys Glu Phe Asn Met lie Glu Gin Ser Gly Pro Pro His 20 25 30 Glu Pro Arg Phe Lys Phe Gin Val Val lie Asn Gly Arg Glu Phe 35 40 45 Pro Pro Ala Glu Ala Gly Ser Lys Lys Val Ala Lys Gin Asp Ala 50 55 60 Ala Met Lys Ala Met Thr lie Leu Leu Glu Glu Ala 65 70 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Lys Ser Pro Val Thr Thr Leu Leu Glu Cys Met His Lys Leu Gly 1 5 10 15 Asn Ser Cys Glu Phe Arg Leu Leu Ser Lys Glu Gly Pro Ala His 20 25 30 Glu Pro Lys Phe Gin Tyr Cys Val Ala Val Gly Ala Gin Thr Phe 35 40 45 Pro Ser Val Ser Ala Pro Ser Lys Lys Val Ala Lys Gin Met Ala 50 55 60 Ala Glu Glu Ala Met Lys Ala Leu His Gly Glu Ala 65 70 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Thr Asn Pro Val Gly Gly Leu Leu Glu Tyr Ala Arg Ser His Gly 1 5 10 15 Phe Ala Ala Glu Phe Lys Leu Val Asp Gin Ser Gly Pro Pro His 20 25 30 Glu Pro Lys Phe Val Tyr Gin Ala Lys Val Gly Gly Arg Trp Phe 35 40 45 Pro Ala Val Cys Ala His Ser Lys Lys Gin Gly Lys Gin Glu Ala 50 55 60 Ala Asp Ala Ala Leu Arg Val Leu lie Gly Glu Asn 65 70 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ala Gly Phe Phe Met Glu Glu Leu Asn Thr Tyr Arg Gin Lys Gin 1 5 10 15 Gly Val Val Leu Lys Tyr Gin Glu Leu Pro Asn Ser Gly Pro Pro 20 25 30 His Asp Arg Arg Phe Thr Phe Gin Val lie lie Asp Gly Arg Glu 35 40 45 Phe Pro Glu Gly Glu Gly Arg Ser Lys Lys Glu Ala Lys Asn Ala 50 55 60 Ala Ala Lys Leu Ala Val Glu lie Leu Asn Lys Glu Lys 65 70 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Gly Asn Tyr lie Gly Leu lie Asn Arg lie Ala Gin Lys Lys Arg 1 5 10 15 Leu Thr Val Asn Tyr Glu Gin Cys Ala Ser Gly Val His Gly Pro 20 25 30 Glu Gly Phe Glu Tyr Lys Cys Lys Met Gly Gin Lys Glu Tyr Ser 35 40 45 lie Gly Thr Gly Ser Thr Lys Gin Glu Ala Lys Gin Leu Ala Ala 50 55 60 Lys Leu Ala Tyr Leu Gin lie Leu Ser Glu Glu 65 70 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Gly Phe Tyr Met Asp Lys Leu Asn Lys Tyr Arg Gin Met His Gly 1 5 10 15 Val Ala lie Thr Tyr Lys Glu Leu Ser Thr Ser Gly Pro Pro His 20 25 30 Asp Arg Arg Phe Thr Phe Gin Val Leu lie Asp Glu Lys Glu Phe 35 40 45 Gly Glu Ala Lys Gly Arg Ser Lys Thr Glu Ala Arg Asn Ala Ala 50 55 60 Ala Lys Leu Ala Val Asp lie Leu Asp Asn Glu Asn 65 70 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Val Gly Asn Tyr lie Gly Leu Val Asn Ser Phe Ala Gin Lys Lys 1 5 10 15 Lys Leu Ser Val Leu lie Glu Gin Cys Glu Pro Asn Ser Glu Leu 20 25 30 Pro Gin Arg Phe lie Cys Lys Cys Lys lie Gly Gin Thr Met Tyr 35 40 45 Gly Thr Gly Ser Gly Val Thr Lys Gin Glu Ala Lys Gin Leu Ala 50 55 60 Ala Lys Glu Ala Tyr Gin Lys Leu Leu Lys Ser Pro 65 70 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Lys Thr Pro lie Ser Leu Leu Gin Glu Tyr Gly Thr Arg lie Gly 1 5 10 15 Lys Thr Pro Val Tyr Asp Leu Leu Lys Ala Glu Gly Gin Ala His 20 25 30 Gin Pro Asn Phe Thr Phe Arg Val Thr Val Gly Asp Thr Ser Cys 35 40 45 Thr Gly Gin Gly Pro Ser Lys Lys Ala Ala Lys His Lys Ala Ala 50 55 60 Glu Val Ala Leu Lys Glu Leu Lys Gly Gly Ser 65 70 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Cys Asn Pro Val Gly Ala Leu Gin Glu Leu Val Val Gin Lys Gly 1 5 10 15 Trp Arg Leu Pro Glu Tyr Thr Val Thr Gin Glu Ser Gly Pro Ala 20 25 30 His Arg Lys Glu Phe Thr Met Thr Cys Arg Val Glu Arg Phe lie 35 40 45 Glu lie Gly Ser Gly Thr Ser Lys Lys Leu Ala Lys Arg Asn Ala 50 55 60 Ala Ala Lys Met Leu Leu Arg Val His Thr Val Pro 65 70 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Gly Pro Ala Cys Cys Arg Val Leu Ser Glu Leu Ser Glu Glu Gin 1 5 10 15 Ala Phe His Val Ser Tyr Leu Asp lie Glu Glu Leu Ser Leu Ser 20 25 30 Gly Leu Cys Gin Cys Leu Val Glu Leu Ser Thr Gin Pro Ala Thr 35 40 45 Val Cys His Gly Ser Ala Thr Thr Arg Glu Ala Ala Arg Gly Glu 50 55 60 Ala Ala Arg Arg Ala Leu Gin Tyr Leu Lys lie Met Ala 65 70 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Glu Thr Pro lie Gin Leu Leu His Glu Phe Gly Thr Lys Thr Gly 1 5 10 15 Asn His Pro Val Tyr Thr Leu Glu Lys Ala Glu Gly Gin Ala His 20 25 30 Asn Pro Ser Phe Thr Phe Arg Leu Val lie Gly Asp lie Thr Ser 35 40 45 Leu Gly Glu Gly Pro Ser Lys Lys Thr Pro Lys Gin Lys Ala Ala 50 55 60 Glu Phe Ala Leu Asn lie Leu Arg Gly Asp Thr 65 70 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Glu Asn Pro Val Gly Ser Leu Gin Glu Leu Ala Val Gin Lys Gly 1 5 10 15 Trp Arg Leu Pro Glu Tyr Thr Val Ala Gin Glu Ser Gly Pro Pro 20 25 30 His Lys Arg Glu Phe Thr lie Thr Cys Arg Val Glu Thr Phe Val 35 40 45 Glu Thr Gly Ser Gly Thr Ser Lys Gin Val Ala Lys Arg Val Ala 50 55 60 Ala Glu Lys Leu Leu Thr Lys Phe Lys Thr lie Ser 65 70 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Thr Asp Tyr Val Lys Met Leu Lys Asp Val Ala Glu Glu Leu Asp 1 5 10 15 Phe Asn Leu Thr Tyr Leu Asp lie Asp Glu Leu Ser Val Asn Gly 20 25 30 Gin Tyr Gin Cys Leu Ala Glu Leu Ser Thr Asn Pro lie Thr Val 35 40 45 Cys His Gly Thr Gly lie Ser Cys Gly Asn Ala His Asn Asp Ala 50 55 60 Ala His Asn Ala Leu Gin Tyr Leu Lys lie Met Cys 65 70 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Lys Thr Pro Met Cys Leu Val Asn Glu Leu Ala Arg Tyr Asn Lys 1 5 10 15 lie Thr His Gin Tyr Arg Leu Thr Glu Glu Arg Gly Pro Ala His 20 25 30 Cys Lys Thr Phe Thr Val Thr Leu Met Leu Gly Asp Glu Glu Tyr 35 40 45 Ser Ala Asp Gly Phe Lys lie Lys Lys Ala Gin His Leu Ala Ala 50 55 60 Ser Lys Ala lie Glu Glu Thr Met Tyr Lys His 65 70 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Lys Phe Pro Ser Arg Phe Ala Leu Pro Pro Pro Leu Gly Ala His 1 5 10 15 Val His His Gly Pro Asn Gly Pro Phe Pro Ser Val Pro Thr Pro 20 25 30 Pro Ser Lys lie Thr Leu Phe Val Gly Lys Gin Lys Phe Val Gly 35 40 45 lie Gly Arg Thr Leu Gin Gin Ala Lys His Asp Ala Ala Ala Arg 50 55 60 Ala Leu Gin Val Leu Lys Thr Gin Ala 65 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Lys Ser Pro lie Ser Gin Val His Glu lie Gly lie Lys Arg Asn 1 5 10 15 Met Thr Val His Phe Lys Val Leu Arg Glu Glu Gly Pro Ala His 20 25 30 Met Lys Asn Phe lie Thr Ala Cys lie Val Gly Ser lie Val Thr 35 40 45 Glu Gly Glu Gly Asn Gly Lys Lys Val Ser Lys Lys Arg Ala Ala 50 55 60 Glu Lys Met Leu Val Glu Leu Gin Lys Leu Pro 65 70 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Asp Asn Pro lie Thr Lys Leu lie Gin Leu Gin Gin Thr Arg Lys 1 5 10 15 Glu Lys Glu Pro lie Phe Glu Leu lie Ala Lys Asn Gly Asn Glu 20 25 30 Thr Ala Arg Arg Arg Glu Phe Val Met Glu Val Ser Ala Ser Gly 35 40 45 Ser Thr Ala Arg Gly Thr Gly Asn Ser Lys Lys Leu Ala Lys Arg 50 55 60 Asn Ala Ala Gin Ala Leu Phe Glu Leu Leu Glu Ala Val 65 70 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 70 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: His Met Lys Glu Gin Leu Leu Tyr Leu Ser Lys Leu Leu Asp Phe 1 5 10 15 Glu Val Asn Phe Ser Asp Tyr Pro Lys Gly Asn His Asn Glu Phe 20 25 30 Leu Thr lie Val Thr Leu Ser Thr His Pro Pro Gin lie Cys His 35 40 45 Gly Val Gly Lys Ser Ser Glu Glu Ser Gin Asn Asp Ala Ala Ser 50 55 60 Asn Ala Leu Lys lie Leu Ser Lys Leu Gly 65 70 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 74 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Lys His Pro Val Ser Ala Leu Met Glu lie Cys Asn Lys Arg Arg 1 5 10 15 Trp Gin Pro Pro Glu Phe Leu Leu Val His Asp Ser Gly Pro Asp 20 25 30 His Arg Lys His Phe Leu Phe Arg Val Leu lie Asn Gly Ser Ala 35 40 45 Tyr Gin Pro Ser Phe Ala Ser Pro Asn Lys Lys Glu Ala Lys Ala 50 55 60 Thr Ala Ala Thr Val Val Leu Gin Ala Met Gly Leu Val Pro 65 70 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Ala Asn Pro Val Thr Val lie Asn Glu Tyr Cys Gin lie Thr Arg 1 5 10 15 Arg Asp Trp Ser Phe Arg lie Glu Ser Val Gly Pro Ser Asn Ser 20 25 30 Pro Thr Phe Tyr Ala Cys Val Asp lie Asp Gly Arg Val Phe Asp 35 40 45 Lys Ala Asp Gly Lys Ser Lys Arg Asp Ala Lys Asn Asn Ala Ala 50 55 60 Lys Leu Ala Val Asp Lys Leu Leu Gly Tyr Val 65 70 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Pro Asp Pro Leu lie Arg Leu Asn Asp Cys Lys Thr Lys Tyr Gly 1 5 10 15 lie Asp lie lie Cys Arg Phe Tyr lie Val Leu Asp Asn Asp Gly 20 25 30 Ser lie lie His Met Cys Tyr Met Arg Thr Gly Ser Ala Glu Ala 35 40 45 Val Ala Lys Gly Arg Ser Lys Lys Glu Ala Lys Arg lie Ala Ala 50 55 60 Lys Asp lie Leu Asp Gin lie Gly Leu 65 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Asp Lys Leu Ala Lys Ser Lys Leu Phe His Lys Tyr Ser Thr Leu 1 5 10 15 Gly His lie Glu Tyr Arg Trp Val Asp Gly Ala Gly Gly Ser Ala 20 25 30 Glu Gly Tyr Val lie Ala Cys lie Phe Asn Gly Lys Glu Val Ala 35 40 45 Arg Ala Trp Gly Ala Asn Gin Lys Asp Ala Gly Ser Arg Ala Ala 50 55 60 Met Gin Ala Leu Glu Val Leu Ala Lys Asp Tyr 65 70 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Lys Asp Pro Lys Thr Arg Leu Gin Glu Tyr Leu Gin Gly Arg His 1 5 10 15 Leu Pro Leu Pro Thr Tyr Leu Val Val Gin Val Arg Gly Glu Ala 20 25 30 His Asp Gin Glu Phe Thr lie His Cys Gin Val Ser Gly Leu Ser 35 40 45 Glu Pro Val Val Gly Thr Gly Ser Ser Arg Arg Lys Ala Glu Gin 50 55 60 Ala Ala Ala Glu Gin Ala Leu Lys Lys Leu Glu Leu Glu 65 70 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 56 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 4..5 (D) OTHER INFORMATION: /note= "Amino acid in position 4 can be Val, lie, Met or Leu." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 5..6 (D) OTHER INFORMATION: /note= "Amino acid in position 5 can be Gly or Ala." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6..7 (D) OTHER INFORMATION: /note= "Amino acid in position 6 can be Leu, Met or Val." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 7..8 (D) OTHER INFORMATION: /note= "Amino acid in position 7 can be Leu, lie, Val or Met." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 8..9 (D) OTHER INFORMATION: /note= "Amino acid in position 8 can be Asn or Gin." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 9..10 (D) OTHER INFORMATION: /note= "Amino acid in position 9 can be Glu or Asp." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 10..11 (D) OTHER INFORMATION: /note= "Amino acid in position 10 can be Tyr, Phe, Leu, lie or Val." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 11..12 (D) OTHER INFORMATION: /note= "Amino acid in position 11 can be Ala or Gly." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 13..14 (D) OTHER INFORMATION: /note= "Amino acid in position 13 can be Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 14..15 (D) OTHER INFORMATION: /note= "Amino acid in position 14 can be Gly or Ala." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 17..18 (D) OTHER INFORMATION: /note= ".Amino acid in position 17 can be Tyr or Phe." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 18..19 (D) OTHER INFORMATION: /note= "Amino acid in position 18 can be Leu, Val, lie or Met." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 19..20 (D) OTHER INFORMATION: /note= ".Amino acid in position 19 can be Leu, Val or lie." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 20..21 (D) OTHER INFORMATION: /note= "Amino acid in position 20 can be Glu or Asp." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 24..25 (D) OTHER INFORMATION: /note= "Amino acid in position 24 can be Ala or Gly." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 26..27 (D) OTHER INFORMATION: /note= "Amino acid in position 26 can be Asp or Glu." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 27..28 (D) OTHER INFORMATION: /note= "Amino acid in position 27 can be Pro, Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 28..29 (D) OTHER INFORMATION: /note= "Amino acid in position 28 can be Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 29..30 (D) OTHER INFORMATION: /note= "Amino acid in position 29 can be Phe or Tyr." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 30..31 (D) OTHER INFORMATION: /note= "Amino acid in position 30 can be Thr, lie, Leu or Val." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 31..32 (D) OTHER INFORMATION: /note= "Amino acid in position 31 can be Phe or Tyr." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 32..33 (D) OTHER INFORMATION: /note= "Amino acid in position 32 can be Val, Leu, Met or Cys." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 33..34 (D) OTHER INFORMATION: /note= "Amino acid in position 33 can be Val, lie, Met or Leu." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 35..36 (D) OTHER INFORMATION: /note= "Amino acid in position 35 can be Gly or Ala." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 36..37 (D) OTHER INFORMATION: /note= "Amino acid in position 36 can be Arg or Lys." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 38..39 (D) OTHER INFORMATION: /note= "Amino acid in position 38 can be Phe or Tyr." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 39..40 (D) OTHER INFORMATION: /note= "Amino acid in position 39 can be Gly or Ala." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 40..41 (D) OTHER INFORMATION: /note= "Amino acid in position 40 can be Ser or Thr." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 41..42 (D) OTHER INFORMATION: /note= "Amino acid in position 41 can be Gly or Ala." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 42..43 (D) OTHER INFORMATION: /note= "Amino acid in position 42 can be Ser or Thr." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 43..44 (D) OTHER INFORMATION: /note= "Amino acid in position 43 can be Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 44..45 (D) OTHER INFORMATION: /note= "Amino acid in position 44 can be Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 45..46 (D) OTHER INFORMATION: /note= "Amino acid in position 45 can be Glu or Asp." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 47..48 (D) OTHER INFORMATION: /note= "Amino acid in position 47 can be Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 48..49 (D) OTHER INFORMATION: /note= "Amino acid in position 48 can be Gin or Asn." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 51..52 (D) OTHER INFORMATION: /note= "Amino acid in position 51 can be Glu, Asp, Lys or Arg." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 53..54 (D) OTHER INFORMATION: /note= "Amino acid in position 53 can be Leu, Val, Met or lie." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 54..55 (D) OTHER INFORMATION: /note= "Amino acid in position 54 can be lie or Val." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 55..56 (D) OTHER INFORMATION: /note= "Amino acid in position 55 can be Leu, lie, Met or Val." (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 55..56 (D) OTHER INFORMATION: /note= "Amino acid in position 56 can be Glu or Asp." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Lys Asn Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Xaa Xaa Pro 1 5 10 15 Glu Xaa Xaa Xaa Xaa Ser Gly Pro Xaa His Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Gly Xaa Xaa Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Ala Xaa Xaa Ala Ala Xaa Ala Xaa Xaa Xaa Xaa 50 55 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: CCGGAATTCN GGNAAAGGTN GA 22 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Pro Gly Lys Val Glu 1 5 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: CGGGATCCNG CTCTCCTTCT GGTCTTNA 28 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Ala Glu Gin Lys Leu 1 5 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: CGGAATTCAA AGACNGGNTA CTGTNGA 27 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Lys Thr Gly Tyr Val Asp 1 5 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: CGGGATCCGA TCGATCNGGG TAATGATCGA TC 32 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Asp Asp Pro lie Asp Asp 1 5 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: CTTTGCACGC ACGTAGGCTC CTG 23 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CGGGATCCAT CTGNCCAGTT CTTCTGTT 28 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Lys lie Leu Ala Ala lie lie Met Lys Lys Asp Ser Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: Pro Gin Asp Ser Gly His His His Tyr Glu Lys Arg Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Arg Glu Pro Arg 1

Claims: WHAT IS CLAIMED IS: 1. A human double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) protein sequence isolated from other cellular materials with which it is naturally associated comprising the amino acid sequence of SEQ ID NO: 2, fragments and analogs thereof having a DRADA-like biological activity. 2. A polynucleotide sequence isolated from other cellular materials with which it is naturally associated and encoding a human double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) protein. 3. The polynucleotide sequence according to claim 2 comprising SEQ ID NO: 1 and fragments thereof. 4. The polynucleotide sequence of claim 2 or claim 3 associated with a detectable label. 5. An expression vector comprising a polynucleotide sequence of claim 2 or claim 3 operably linked to an expression control sequence. 6. A host cell transformed with an expression vector of Claim 5. 7. A polyclonal or monoclonal antibody generated by use of a human double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) protein or fragments thereof having DRADA-like biological activity as an immunogen. 8. A DNA probe comprising an oligonucleotide fragment of the polynucleotide sequence of claim 2, claim 3 , or a complementary strand thereof. 9. The probe of claim 8 further comprising a- detectable label. 10. A method of identifying compounds which specifically bind to a selected double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) DNA sequence, comprising the steps of contacting said DRADA DNA sequence with a test compound to permit binding of the test compound to the DNA sequence; and determining the amount of test compound which is bound to the DNA sequence. 11. The method according to claim 10 wherein said DNA sequence is selected from the group consisting of a DRADA double stranded RNA binding motif (DRBM) sequence and a DRADA catalytic domain. 12. The method according to claim 10 wherein said DRADA DNA sequence is immobilized on a solid support. 13. The method according to claim 10 wherein the normal target of said DRADA sequence is also incubated with said DNA sequence and said test compound to permit binding between said target and said DNA sequence; determining the amount of target protein which is bound to said DNA sequence, wherein inhibition of binding of target to DRADA sequence by the test compound indicates binding of the test compound to the DRADA DNA sequence. 14. A method for diagnosing a disorder characterized by defective or deficient double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) expression comprising contacting a sample of tissue from a patient with a diagnostic reagent selected from the group consisting of a polyclonal antibody to DRADA, a monoclonal antibody to DRADA, an oligonucleotide sequence complementary to a DNA sequence encoding DRADA, a protein sequence of DRADA or fragment thereof, said reagent associated with a detectable label, and measuring the amount of DRADA in said tissue by the association between said reagent and DRADA in said tissue. 15. A compound capable of enhancing or inhibiting the activity of double stranded ribonucleic acid adenosine deaminase enzyme (DRADA) , produced by screening a group of compounds with a DRADA protein, DRADA DNA sequence or anti-DRADA antibody. 16. A fragment of the human double stranded ribonucleic acid adenosine deaminase enzyme protein sequence of claim 1 selected from the group consisting of the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, and the amino acid sequence of SEQ ID NO: 5. 17. The use of a human DRADA protein sequence according to claim 1 in generating a polyclonal or monoclonal antibody. 18. The use of a protein sequence of claim 1, a polynucleotide sequence of claim 2, or an antibody of claim 7 in preparing a medicament for treatment of a neurodegenerative condition.

Inventors: NISHIKURA KAZUKO, NISHIKURA, KAZUKO
Applicants: WISTAR INST, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Application year: 1995
Main classification: C12N9
IPC codes: A61K31, A61K38, A61K48, A61P9, A61P25, A61P31, C07H21, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12Q1, G01N33